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Section 1
Assessment and management of people with 
substance use and related disorders
1.1 Assessment of people with substance use and related 
disorders who attend HAARP service sites
People who use drugs often present to health workers at drop-in 
centres (DICs) with health conditions that are consequences of drug 
use and dependence. People using substances usually have multiple 
medical problems that need to be assessed comprehensively to plan 
and implement appropriate treatment.
With appropriate attitudes, knowledge and skills, health workers can be the 
most powerful motivators for change in the lives of people who use drugs. Their 
role is vital in screening, treating and referring people who use drugs.
1.1.1 Role of health workers in helping people who use drugs
Box: The tasks of health workers
•	 Establish the relationship of drug use to the presented complaints.
•	 Diagnose drug use and related disorders.
•	 Assess specific problems related to drug use (harmful use,    
 problem use, dependent use):
 – drug-induced disorders
 – concurrent disorders.
•	 Assess and manage intoxication and withdrawal.
•	 Explore the consequences of the patient’s drug dependence on the following:
 – physical health
 – mental health
 – social and family relationships
 – economic and employment status.
•	 Determine the motivation and expectations of people using drugs in terms of  
treatment.
•	 Offer the appropriate intervention (direct intervention at the service site and referral).
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Relationship between the health worker and people who use drugs: 
Treatment planning is a joint process between the health worker and 
people who use drugs. The health worker should be flexible and offer a 
range of services to people who use drugs. Often, multiple interactions are 
necessary between the health worker and the person using drugs before 
the latter is ready to engage in treatment. A partnership between the health 
worker and people who use drugs is vital to retaining users in treatment.
A fundamental task is to create a healthy relationship, in which the 
person using drugs does not feel judged and is comfortable disclosing 
information related to drug use and other behaviour, including sexual 
risk behaviour. The information provided by the person is confidential, 
and he or she should feel confident discussing with the health worker 
issues related to drug use. Developing a relationship based on trust 
between the health worker and the drug user requires the health worker 
to be consistent, honest, uncritical, empathetic, accepting and non-
judgmental. Only a user-friendly relationship is capable of effecting 
behaviour change in people who use drugs.
Motivational interview
Where possible motivational interview techniques should be used 
from the first contact, as there is robust evidence of them having 
helped people to change dependent behaviour. Motivational dialogue 
is initially more important than slavishly checking for dependence 
symptoms, if the intervention is to be brief.
Four general principles and five basic skills of motivational 
interviews
Principles:
1. Express empathy: Listen in a supportive and reflective manner, 
demonstrate that you understand the client’s concerns and feelings, 
and encourage a non-judgmental and collaborative relationship.
2. Develop discrepancy: The client, rather than the clinician, should 
present the arguments for change. Change is motivated by a 
perceived discrepancy between present behaviour and important 
personal goals or values.
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3. Roll with resistance: Avoid arguing for change. Do not directly 
oppose the client. Invite new perspectives but do not impose them. 
The resistance that a person offers can be turned or reframed to 
move the person towards change. The client is the primary source of 
answers and solutions. Resistance is a signal to respond differently; 
the clinician turns the questions or problems back to the person.
4. Support self-efficacy: A person’s belief in the possibility of change is 
an important motivator. The client, not the clinician, is responsible 
for choosing and carrying out change. The clinician’s own belief in 
the person’s ability to change becomes a self-fulfilling prophecy.
The World Health Organization (WHO) has online training courses on 
motivational interviews, such as the Alcohol, Smoking and Substance 
Involvement Screening Test for Trainers.
Skills:
1. Open-ended questions
2. Reflective listening
3. Self-motivational statements
4. Affirmation
5. Summary statement.
1.1.2 Substance use, dependence and drug-induced disorders
Certain terms related to drug use need to be defined and explained to ensure 
that health workers describe the same phenomena when they communicate 
with persons using drugs and with each other.
1.1.2.1 Drugs of use
Central nervous system (CNS) depressants (old system of classification):
•	 Alcohol
•	 Sedative/hypnotics and anxiolytics
 – benzodiazepines
 – barbiturates
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•	 Opioids (e.g. opium, heroin, morphine, codeine, methadone, 
tramadol, propoxyphene and buprenorphine)
•	 Inhalants (e.g. solvents and glue).
CNS stimulants:
•	 Amphetamine-type stimulants (ATS), e.g. methamphetamine (yama 
and yaba), d-amphetamine, ecstasy
•	 Cocaine and crack cocaine
•	 Nicotine
Hallucinogens:
•	 Lysergic acid diethylamide (LSD)
•	 Ketamine
•	 Phencyclidine (PCP)
Cannabis:
•	 Marijuana (ganja, pot, weed)
1.1.2.2 Reasons for substance use
•	 Tradition: as part of symbolic or religious ceremonies.
•	 Self-medication: to relieve feelings of fear, anxiety and depression.
•	 Pain relief: to relieve physical symptoms of pain.
•	 Enjoyment: for their pleasurable effects, for fun.
•	 Lifestyle: peer pressure.
•	 Alleviation: to reduce misery, distress related to poverty and 
disadvantage.
•	 Genetics: inherent biological propensity of a person.
1.1.2.3 Levels of substance use
•	 Experimental: single or short-term use that is motivated by curiosity 
or a desire to experience new feelings or moods.
•	 Recreational: controlled use in social settings.
•	 Circumstantial: use in situations where specific tasks are to be 
performed or freedom from pain is sought.
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•	 Regular: use many times in the month.
•	 Compulsive: persistent, frequent, high-dose use that produces 
psychological and physical dependence.
1.1.2.4 Commonly used terms
Substance use: the use of any substance that alters sensory experiences 
and provides rewards or pleasure or alleviates discomfort (Figure 1)
Harmful use: a pattern of use that damages health
Hazardous use: a pattern of use that increases the risk of harmful 
consequences
Problem use: a pattern of use with consequences in one or more 
domains of the person’s life (e.g. alcohol use leading to liver disease)
Binge use: the cyclical consumption of large amounts of substances.
Figure 1 Levels of substance use
* Needs specialist services.
Source: D Raistrick et al. 2006. A review of the effectiveness of treatment for alcohol 
problems. National Treatment Agency for Substance Misuse, London.
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Diagnosing substance dependence
Drug dependence is a maladaptive pattern of drug use leading to 
clinically significant impairment or distress in relation to behaviour, 
thought processes and physical change. This happens after the 
repeated use of one or more illicit substances.
WHO’s International Classification of Diseases (ICD) 10 has the following 
syndromes, coded F10–F19:
F10. Mental and behavioural disorders due to use of alcohol
F11. Mental and behavioural disorders due to use of opioids
F12. Mental and behavioural disorders due to use of cannabinoids
F13. Mental and behavioural disorders due to use of sedatives or   
 hypnotics
F14. Mental and behavioural disorders due to use of cocaine
F15. Mental and behavioural disorders due to use of other   
 stimulants including caffeine
F16. Mental and behavioural disorders due to use of hallucinogens
F17. Mental and behavioural disorders due to use of tobacco
F18. Mental and behavioural disorders due to use of volatile solvents
F19. Mental and behavioural disorders due to use of multiple   
 drugs and other psychoactive substances.
In ICD-10, the dependence syndrome is defined as a cluster of 
behavioural, cognitive and physiological phenomena that develop 
after repeated substance use. A definite diagnosis of the dependence 
syndrome usually should be made only if three or more of the following 
have been present together at some time during the previous year:
•	 evidence of tolerance.
•	 physiological withdrawal when substance use was ceased or 
reduced.
•	 strong desire or sense of compulsion to take the substance.
•	 difficulty in controlling substance-taking behaviour in terms of its 
initiation, termination or quantity.
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•	 progressive neglect of alternative pleasures or interests.
•	 persistence with substance use despite clear evidence of overtly 
harmful consequences.
1.1.2.5 Substance-induced disorders
This category includes disorders that are associated with or caused by 
drugs. These disorders are better accounted for by excessive use (e.g. 
intoxication) or discontinuation of the drug (e.g. withdrawal).
Intoxication: This diagnosis is made when the patient is under the 
influence of the drug, leading to maladaptive behaviour. Intoxication 
is specific to a particular class of drugs. Intoxication delirium is a 
severe form of intoxication. It is a transient condition following the 
administration of a psychoactive substance, resulting in disturbances 
to consciousness, cognition and thought process, perception, mood 
or behaviour, or other psycho-physiological functions and responses.
Withdrawal: This diagnosis is made when the person experiences 
a distinct syndrome characteristic of the discontinuation of a drug. 
The onset is within hours or days of stopping or reducing the drug. 
Acute withdrawal for most drugs lasts 7–10 days. Withdrawal delirium 
is a more severe form of withdrawal.
Drug-induced mood disorders: A spectrum of clinically significant 
mood disturbances can occur within 30 days of drug intake or during 
intoxication or withdrawal that are not better explained by other causes.
Drug-induced anxiety disorders: A spectrum of clinically significant 
anxiety disturbances can occur within 30 days of drug intake or during 
intoxication or withdrawal that are not better explained by other causes.
Drug-induced psychotic disorders: A spectrum of clinically significant 
hallucinations, delusions and behavioural disturbances can occur within 
30 days of drug intake or during intoxication or withdrawal that are not 
better explained by other causes.
Factors that contribute to the negative consequences of substance use: 
In general, drugs that are most highly rewarding are associated with 
more harmful patterns of use. These drugs have characteristics that 
enable the rapid entry of a substance into the brain, including rapid 
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absorption, rapid onset of action, rapid entry into the CNS, high 
potency, a brief duration of action (short half-life), high purity, water 
solubility (for injectable use) and/or high volatility (ability to vaporise 
if smoked).
As various drugs have different abuse liability, health workers must be 
aware of the following factors that contribute to this:
•	 Short half-life: Drugs with a shorter half-life have to be taken 
frequently and develop dependence more quickly (e.g. heroin 
induces greater dependency than methadone; Figure 2).
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Figure 2 Comparison of heroin and methadone
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Source: Dole VP, Nyswamder ME, ‘Pharmacological treatment of narcotic addiction’. 
8th Nartan B. Memorial Award Lecture. National Institute on Drug Abuse, Bethesda, 
MD, 1982.
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•	 Rapid onset and offset of action: Drugs that act quickly on the brain 
induce greater dependence.
•	 Route of administration: Injecting is a more efficient means of drug 
delivery than ‘chasing’ the drug, with intravenous injection more 
efficient than intramuscular.
1.1.2.6 Medical harms associated with injecting drugs
•	 Injection-related injuries
 – Bruising
 – Scarring
 – Swelling and inflammation including hives
 – Venous or arterial injury
 – Ulcers
•	 Injection-related infections
 – Cellulitis and abscesses
 – Thrombophlebitis
•	 Complications of injection-related infections
 – Bacteraemia and septicaemia
 – Musculoskeletal infections
 – Endovascular complications
 – Tetanus
•	 Injection-related infectious diseases
 – HIV
 – Hepatitis C
 – Hepatitis B
•	 Other common infections
 – Sexually transmitted infections
 – Herpes simplex virus 2 infection
 – Tuberculosis and other respiratory infections. People who 
inject drugs have a 10-fold greater risk of community-acquired 
pneumonia. As tobacco smoking is common, respiratory 
clearance mechanisms may be impaired. Drug users are at 
an increased risk for aspiration, particularly during overdose. 
Inhaling or snorting drugs predisposes drug users to upper 
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respiratory tract infections, including sinusitis and, in rare 
instances, nasal septum abscesses.
 – Embolization, such as blood clots, bacteria or undissolved 
injected drug in the brain (brain abscesses and meningitis), 
heart valves (endocarditis), joints (septic arthritis), fingers 
and toes (gangrene), bones (osteomyelitis), and other organs 
(spleen and liver abscesses, etc).
•	 Other common health problems
 – Pain
 – Constipation
 – Poor dental health and hygiene
For details related to this section, please refer to World Health 
Organization Regional Office for South-East Asia 2009. Clinical manual 
on managing common health problems of injecting drug users. 
Available at http://203.90.70.117/PDS_DOCS/B3230.pdf. 
1.1.3 Assessment of substance use and related disorders
Comprehensive assessment is essential for the continuing care of people 
who use drugs. Assessment skills are important for health workers, as they 
help people who use drugs to get engaged in treatment and begin the 
process of change.
1.1.3.1 Aims of assessment
•	 Treat any emergency or acute problems.
•	 Confirm that the patient is taking drugs (history, examination and 
urine analyses).
•	 Assess the degree of dependence.
•	 Identify the complications of drug use and assess risk behaviour.
•	 Identify other medical and mental health problems.
•	 Advise on harm reduction, including, if appropriate, access to 
sterile needles and syringes, testing for HIV, and immunisation 
against hepatitis B.
•	 Assess withdrawal syndrome.
•	 Assess intoxication.
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•	 Determine the patient’s expectations of treatment and the degree 
of motivation to change.
•	 Assess the most appropriate level of expertise required to manage 
the patient (which may alter over time) and refer for appropriate 
care (Figure 3).
Figure 3 Assessment of drug use
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1.1.3.2 Assessment and diagnosis of drug dependence
A. Drug history
i. Reasons for presentation
•	 In crisis because of overdose (incidental, accidental or both), 
financial and/or occupational crisis, physical health, relationship or 
family problems, loss of control over use, etc.
•	 Brought in by a concerned parent, relative, spouse, employer, 
friend or social worker.
•	 Wants help for drug dependence and be motivated to change 
behaviour.
•	 Referred by the police.
•	 Usual source of drugs not available.
•	 Referred by another medical practitioner.
•	 Suffering from mental illness (psychiatric co-morbidity).
•	 Pregnancy.
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ii. Past and current drug use (past 4 weeks)
•	 Age when starting drug use, including alcohol and nicotine.
•	 Types and quantities of drugs taken, including concomitant alcohol 
and other drug use.
•	 Frequency of use and routes of administration.
•	 Experience of overdoses.
•	 Periods of abstinence and what helped prolonged abstinence.
•	 Triggers for relapse.
•	 Symptoms experienced when unable to obtain drugs.
•	 Cost of drug and alcohol use.
•	 Symptoms of dependence.
•	 Drug-funding activities.
•	 Social network.
iii. History of injecting and risk of HIV and hepatitis
•	 Past history.
•	 Reasons for change to injecting.
•	 Source(s) of needles and syringes.
•	 Needle-sharing behaviour, including lending and borrowing 
injection equipment.
•	 Knowledge of how to inject safely or its lack.
•	 Cleaning equipment before and after use or not.
•	 Disposal of used equipment.
•	 Knowledge of HIV and hepatitis B and C prevention and 
transmission.
•	 Use of condoms.
iv. Medical history
•	 Complications of drug use: abscesses, thromboses, viral illnesses 
and respiratory problems.
•	 Hepatitis B and C status, if known.
•	 HIV status, if known.
•	 Last menstrual period.
•	 Operations, accidents and head injuries or any other medical condition.
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v. Psychiatric history
•	 Any psychiatric consultations.
•	 Any history of overdose, accidental or deliberate.
vi. Forensic history
•	 Any outstanding criminal charges.
•	 Past and present contact with the criminal justice system.
•	 Past custodial sentences.
vii. Social history
•	 Family situation.
•	 Employment situation.
•	 Housing situation.
•	 Financial situation including debts.
viii. Past contact with treatment services
•	 Previous efforts to reduce or stop drug taking.
•	 Contacts with doctors, social services, community services and 
drug treatment centres.
•	 Previous admissions for rehabilitation, how long they lasted and the 
causes of any relapses.
ix. Other relevant history
•	 Drug and alcohol use in partner, spouse and other family members.
•	 Impact of drug use on other aspects of the patient’s life.
B. Examination
i. Assessing motivation
Is the client motivated to stop or change the pattern of drug use or to 
make other changes in his or her life? In which stage of behaviour change 
is the person? Is the person in pre-contemplation, contemplation, 
preparation, maintenance/termination or relapse?
ii. Assessing mental health
Are there coexisting psychiatric problems?
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iii. Assessing general health
•	 General: anaemia, nutritional status, dental and overall hygiene.
•	 Skin: needle marks, tattoos, skin abscesses, scabies and open wounds.
•	 Route specific: smoking (asthma), injecting (abscesses, cellulitis).
•	 Sharing needles, syringes and injection equipment and implications 
for hepatitis B and C, HIV and other blood-borne infections.
•	 Drug-related: side-effects (e.g. constipation), overdose (e.g. 
respiratory depression) and withdrawal (e.g. irritability).
C. Special investigations with full informed consent
Haematological investigations
•	 Haemoglobin, complete blood picture.
•	 Liver function tests.
•	 Tests for hepatitis B and C and HIV.
•	 Venereal disease research laboratory test for syphilis.
•	 Chest x-ray.
•	 If in a delirious withdrawal state, may need additional investigations 
(e.g. serum electrolytes, sodium and potassium and blood sugar levels).
•	 Drug urine analysis, if facility is available.
1.1.4 Treatment planning for substance use and related disorders
1.1.4.1 Aims of treatment
•	 Help the patient to remain healthy until, with appropriate care 
and support, he or she can achieve improved socio-occupational 
functioning, controlled drug use or a drug-free life.
•	 Reduce the individual’s use of illicit or non-prescribed drugs.
•	 Deal with the problems related to drug use including withdrawal 
and intoxication.
•	 Reduce the dangers associated with drug misuse, especially the 
risk of HIV, hepatitis B and C, and other blood-borne infections 
caused by injecting and sharing injecting paraphernalia.
•	 Reduce foetal exposure to drugs.
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1.1.4.2 Various interventions in the process of treatment
•	 Contact with a person using drugs: This begins with attendance at 
a DIC or contact with an outreach worker.
•	 Assessment: Drug use and related problems need careful 
consideration of, notably, living conditions, family issues and legal 
problems. It is important to determine if there is any need for 
urgent medical care.
•	 Diagnosis: Are there coexisting psychiatric or medical disorders to 
evaluated. Referral to a specialist in any or all of these areas may be 
necessary. Evaluate the presence and severity of dependence on 
any specific drug and the extent of other drug or alcohol use.
•	 Therapy: Various options depend on client choice, assessment and 
the availability of various therapies.
•	 Follow up and long-term support: This is probably the most 
important and neglected area because of the skills and time of 
health workers required, frustration because of relapse, and loss of 
contact with the patient.
•	 Resource map: Map the nearest secondary and tertiary facilities for 
HIV and AIDS treatment and care, as well as mental health services.
1.2 Management of withdrawal syndrome (detoxification)
Management of withdrawal, or detoxification, is the first step in drug 
dependence treatment; however, as a standalone treatment, detoxification has 
very little value.
1.2.1 Introduction to management of withdrawal (detoxification)
Management of withdrawal, or detoxification, diminishes the pain and 
discomfort the person feels when withdrawing over a short period 
from the drug of dependence (such as heroin, a sedative or hypnotic, 
ATS, or alcohol) by providing medical and psychological support. A 
detoxification protocol has twin objectives:
•	 Provide safe and humane treatment to enable the individual to 
remain abstinent during the acute phase of withdrawal.
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•	 Facilitate the patient’s transition to a drug-free state.
Drug dependence is an enduring illness, and abstinence rates following 
treatment are alarmingly low. High relapse rates have nothing to do with 
lack of will power. The long-term use of dependence-inducing drugs 
changes the brain chemistry in such a way that the person experiences 
distress or cravings in their absence. Hence, long-term treatment is 
necessary to reduce drug-related harm.
It is important to provide an environment that increases the likelihood 
of a patient continuing in treatment after detoxification and to make 
referrals from the service site or DIC for subsequent treatment. 
Identifying coexisting medical or psychiatric problems and treating 
them or referring the client for additional care following detoxification 
is essential. Psychosocial services can address issues related to health 
(e.g. HIV and hepatitis C) and relapse prevention. Health workers at 
HAARP service sites can explore family, legal and vocational problems 
that may need further referral.
Successful detoxification entails not only safely completing the 
short-term treatment of withdrawal but also treatment retention and 
participation in long-term management (Figure 4). However, many 
young people using drugs believe that withdrawal management is all 
they need to get rid of their habit and remain off drugs. When they 
return to the service site for detoxification a second or third time, they 
are more realistic and understand the need for long-term management.
Figure 4 Detoxification services
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1.2.1.1 General principles of drug detoxification services
•	 Carry out a comprehensive assessment to help with the treatment plan.
•	 Prepare the patient for the management of withdrawal.
•	 Provide factual, realistic information about drugs and withdrawal 
symptoms to alleviate the anxiety and fear associated with 
withdrawal symptoms.
•	 Ask the person undergoing detoxification to visit the service site 
every day during withdrawal management.
•	 Request a family member to accompany the person, if possible.
•	 The doctor should advise and direct the prescription of 
medications used for detoxification.
•	 Health workers such as nurses are responsible for monitoring 
withdrawal, dispensing medication and educating the patient on 
how to manage withdrawal.
•	 Advise the patient on good nutrition and avoiding dehydration. 
General vitamin and mineral supplements can be recommended, 
as many drug users are malnourished.
•	 Rigorous physical exercise may prolong withdrawal and worsen 
distress. Warm baths may be helpful.
•	 Encourage people undergoing detoxification to engage in calming 
practices such as relaxation exercises and meditation.
•	 If the patient becomes confused or behaviourally disturbed during 
withdrawal, arrange for hospitalisation to manage the symptoms.
1.2.1.2 Psychological interventions
Brief interventions: Offer opportunistic brief interventions focused on 
motivation to people in limited contact with the drug services (e.g. 
those attending a needle and syringe program). These interventions 
should aim to increase motivation to change behaviour and provide 
non-judgmental feedback.
Self-help: Provide people who use drugs with information about local 
self-help and support groups.
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1.2.1.3 Management of opioid withdrawal
In general, it is wise to avoid poly-pharmacy to treat opioid withdrawal; 
provide effective treatment with opioid medications (methadone or 
buprenorphine) or clonidine.
1.2.1.4 Symptoms and signs of opioid withdrawal
Withdrawal from opioids is associated with a specific withdrawal 
syndrome with the following symptoms:
sweating nausea and vomiting
watering eyes diarrhoea
running nose increased bowel sounds
yawning sleep disturbance
hot and cold flushes restlessness
goose bumps generalised aches and pains
tremors (shakes) rapid heart rate
loss of appetite elevated blood pressure
abdominal cramps dilated pupils
The signs and symptoms can be assessed by structured instruments 
such as the short opioid withdrawal scale (see Appendix).
1.2.1.5 Factors influencing the severity of withdrawal symptoms
The intensity, peak and course of withdrawal can differ between short-
acting and long-acting opioids.
Table 1 Onset, peak and duration of opioid withdrawal
Drug
Duration of 
effects
Onset of 
withdrawal 
from the last 
dose
Peak 
withdrawal 
effects
Duration of 
withdrawal
Heroin 4 hours 8–12 hours 36–72 hours 7–10 days
Morphine 4–5 hours 8–12 hours 36–72 hours 7–10 days
Codeine 4 hours 8–12 hours 36–72 hours 7–10 days
Methadone 8–12 hours 36–72 hours 96–144 hours 10–20 days
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When opioids are stopped, the severity of withdrawal symptoms 
depends on a number of factors:
•	 Amount of opioids used daily: In general, the more opioids 
ingested daily, the more severe the withdrawal syndrome.
•	 Duration and regularity of use: Generally, the more intermittent 
the drug use, the less severe the withdrawal. Consistent use over a 
longer duration appears to produce more severe symptoms.
•	 Psychological and individual factors: Personality and state of mind 
can influence the severity of withdrawal, as can general physical 
health and ability to cope with stress.
1.2.1.6 Treatment of opioid withdrawal
Patients should drink plenty of fluids during withdrawal to replace the 
fluids lost to excessive sweating and diarrhoea (health workers should 
be aware of the possibility of compromised renal function). Vitamin 
supplements can also be provided. For mild opioid withdrawal, 
supportive care and symptom management suffice. For moderate and 
severe withdrawal, pharmacological treatment with opioid medications 
or clonidine may be required.
Both methadone and buprenorphine are listed on the WHO Essential Medicines 
List. They are highly effective in the management of opioid dependency as part 
of a maintenance regime. 
Evidence of effective opioid withdrawal management also exists for methadone 
and buprenorphine. Opioid withdrawal is not a life-threatening condition, but 
untreated opioid toxicity can be fatal.
Methadone
Evidence shows that methadone is useful in the management of 
moderate-to-severe opioid withdrawal and effective in controlling 
withdrawal symptoms. The preparation of choice is methadone 
mixture. As methadone is long acting, a stable daily dose is easy to 
achieve. It is also easy to determine the amount of methadone required 
to achieve the optimal dose for controlling withdrawal symptoms. 
Further, methadone is less likely to be injected and, if administered in a 
supervised setting, has less potential for diversion. All patients starting 
on methadone must be informed of the risk of toxicity and overdose.
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Considering the potential of opium toxicity, the dosage regimen must 
take the following into account:
•	 Tolerance to opioids can be affected by a number of factors 
and significantly influences an individual’s risk of toxicity. Of 
particular importance in assessing this are the client’s report of 
the current quantity ingested and dosing frequency and route 
of administration. It is important to be wary of possible incorrect 
reporting of intake. A person’s tolerance to methadone can be 
significantly reduced within 3–4 days of not using opioids, so 
caution must be exercised after this time, with careful re-titration 
from the starting dose.
•	 Any use of other depressant drugs such as alcohol and 
benzodiazepines must be known.
•	 The long half-life of methadone means cumulative toxicity may 
develop. For this reason, a patient should be reviewed regularly for 
signs of intoxication and the dose omitted or reduced if there is any 
sign of drowsiness or other evidence of opioid toxicity.
•	 Inappropriate dosing can result in a potentially fatal overdose, 
particularly in the first few days.
The onset of action should be evident within half an hour, with peak 
plasma levels being reached within approximately 2–4 hours of dosing.
Table 2 Suggested methadone dosing to manage opioid withdrawal
Day Dose in milligrams
1–4 30
5–8 35
9 30
10 25
11 20
12 15
13 10
14  5
15  0
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There can be flexibility in the regimen shown in Table 2, depending 
on the symptoms exhibited by the person experiencing withdrawal. 
Methadone equivalents for different opioids are provided in Table 3. A 
patient who has been using large amounts of illicit opioids will require 
larger doses of methadone. In principle, methadone dose reduction 
for heavy drug users should be more gradual than for others. It may be 
necessary to maintain the methadone dose at a particular level over 
a few days to ease the patient’s distress and anxiety and strengthen 
his or her sense of control. Dose reduction should be accompanied 
by psychological support from health workers at service sites. Some 
symptoms that are not completely alleviated by the use of methadone 
can be resolved with symptomatic treatment, when required.
The detoxification program should be reviewed regularly and remain 
flexible, while taking into consideration the risk of relapse into illicit 
drug use and patients’ anxieties about the speed of reduction. Factors 
such as an increase in heroin and/or other drug use or worsening of 
the patient’s physical, psychological or social well-being may warrant 
slowing down of the reduction rate. Towards the end of detoxification, 
the dose reduction may be slower than 1–2 milligrams (mg) per week.
Table 3 Methadone equivalents
Opioids Dose equivalent to 1 mg of methadone
Heroin 1.0–2.0 mg
Morphine 3.0–4.0 mg
Oxycodone 1.5 mg
Hydromorphone 0.5 mg
Codeine 30.0 mg
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Tincture opium
This preparation of opium in alcohol and water is used to treat opioid 
withdrawal in some countries, notably Laos and Myanmar. Despite its 
use in clinical settings, evidence that tincture opium is an effective 
treatment for heroin withdrawal is ill established, unlike the evidence 
supporting the effectiveness of methadone or buprenorphine.
Buprenorphine
Buprenorphine is a partial μ-receptor agonist and K-receptor antagonist. 
This drug is the best opioid medication for managing moderate-to-
severe opioid withdrawal. It has faster action onset than methadone and 
is superior in controlling withdrawal symptoms. In addition, it is safer 
than methadone. It is less likely to produce severe respiratory depression 
(reported cases of respiratory depression are usually due to the 
concomitant use of benzodiazepines). Like methadone, it is long acting 
and effectively administered by a non-parenteral, sublingual route. The 
drug’s disadvantage is that it is readily soluble and injectable, requiring 
that all efforts be taken to supervise daily dispensing. Being a partial 
μ-receptor agonist, buprenorphine may precipitate withdrawal symptoms 
if given too soon following the use of a pure opioid agonist such as heroin. 
It should therefore be given after the emergence of opioid withdrawal 
symptoms. See Table 4 for suggested dosing to manage withdrawal.
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Table 4 Buprenorphine dosing to manage opioid withdrawal
Day Dose in milligrams
1 6
2 8
3 10
4 8
5 4
Detoxification using buprenorphine is safe, quick and effective, 
but it is more expensive than methadone. Also available is a 
combination of buprenorphine and naloxone that is less likely to 
be diverted for injection.
The same principles as for methadone apply when planning a 
buprenorphine detoxification regimen.
Table 5 Buprenorphine dose reduction during detoxification
Daily buprenorphine dose Reduction rate
Above 16 mg 4 mg every 1–2 weeks
8–16 mg 2–4 mg every 1–2 weeks
2–8 mg 2 mg/week or fortnight
Below 2 mg Reduce by 0.4–0.8 mg/week
Codeine-based drugs
These drugs are rarely recommended for managing opioid withdrawal, 
even though practitioners in different parts of the world use it. As 
an opioid, codeine alleviates opioid withdrawal symptoms. The 
disadvantage is that the drug has a short half-life and requires repeated 
tablet-taking throughout the day, which may actually reinforce patterns 
of drug-taking behaviour. The abuse of codeine-based drugs is 
widespread in certain Asian countries.
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Propoxyphene
Though useful for medical analgesia, propoxyphene is a common 
street opioid in South Asia, notably in Bhutan, India and Nepal. Some 
people have used propoxyphene in a withdrawal regimen with a 
dosing schedule of 2–3 times daily. Often, a combination of a non-
opioid medication with propoxyphene is required to control withdrawal 
symptoms, as propoxyphene is unable by itself to alleviate all withdrawal 
symptoms. It has a number of active metabolites. In general, it is not 
recommended for the effective treatment of opioid withdrawal.
Tramadol
This drug is a centrally acting analgesic with an atypical pharmacology; 
it weakly binds to μ-opioid receptors and additionally inhibits reuptake 
of serotonin and noradrenalin neurotransmitters. Because of its mild 
opioid-agonist effects, tramadol can suppress withdrawal but not as 
completely as other opioids. Even with orally administered doses of 
up to 400 mg, tramadol may produce μ-agonist effects equivalent 
to only 5–10 mg of hydromorphone similarly administered. The 
therapeutic use of tramadol to treat moderate-to-severe pain may 
lead to subsequent dependence on the drug, especially in patients 
with a history of drug misuse. Tramadol is not licensed anywhere for 
managing opioid withdrawal and should not be used for this purpose. 
On the contrary, the following needs to be considered before using 
tramadol for managing opioid withdrawal.
•	 As tramadol is a non-scheduled opioid, it is more readily available 
than other opioid analgesics.
•	 The inadequate efficacy of tramadol may prompt an increase in the 
number of doses, which can lead to tramadol dependence.
•	 Seizures and cerebral depressions are serious CNS disturbances 
caused by tramadol overdose.
•	 Tramadol is often combined with benzodiazepines, which increases 
the potential for overdose.
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Withdrawal management using non-opioid medications
Clonidine
The α2-adrenergic agonist drug clonidine is marketed as an 
antihypertensive. It has been used to manage opioid withdrawal and 
can be used in outpatient settings such as service sites and DICs. 
Clonidine is now accepted as an alternative to gradual methadone 
reduction. At dosages of 0.6–2.0 mg/day, clonidine reduces many 
of the autonomic components of opioid withdrawal syndrome. 
However, opioid withdrawal symptoms such as craving, lethargy, sleep 
disturbance, restlessness and muscle aches are not well suppressed. 
Clonidine is only mildly analgesic.
As sedation and hypotension are major side-effects, the careful 
monitoring of blood pressure and heart rate is required to minimise 
the risk of significant hypotension and/or syncope. Clonidine should 
be stopped if the blood pressure drops below 90/50 millimetres of 
mercury (mmHg) or if the heart rate is slower than 50 beats per minute.
Table 6 Clonidine dosing for the management of opioid withdrawal
Day Dose
1 150 micrograms 3 times daily
2 150–300 micrograms 3 times daily
3 150–300 micrograms 3 times daily
4 75 micrograms 3 times daily
5 75 micrograms twice daily
Other drugs and supportive measures
Insomnia, or sleep disturbance, is one of the most distressing withdrawal 
symptoms. The problem may not be significant for people receiving 
opioid medications for withdrawal. In others receiving only symptomatic 
treatment for opioid withdrawal, sedating medications are needed to deal 
with sleep disturbance. Commonly used sedating drugs include sedating 
antidepressants (e.g. trazodone and amitriptyline), antihistamines (e.g. 
chlorpheniramine maleate) and benzodiazepines (e.g. diazepam).
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Benzodiazepines must be given carefully, if at all, to people withdrawing 
from opioids, especially those treated as outpatients at service sites 
due to the high risk of respiratory depression. As benzodiazepines can 
be significantly misused and cause a range of problems (see section 
1.2.4), it is better to prescribe sedating antidepressants (e.g. trazodone) 
for insomnia. While prescribing conventional antidepressants such as 
amitriptyline, it is necessary to watch out for side-effects such as dry 
mouth, blurred vision, constipation and hypotension. Antipsychotics 
such as chlorpromazine and haloperidol are not indicated for managing 
withdrawal, as they can produce alarming extrapyramidal side-effects 
(see the drug tables in the Appendix and section 2.3.5).
Table 7 Medications for treating ancillary withdrawal symptoms
Symptoms Drug Dose
Pain or muscle 
cramps
Ibuprofen
Ketorolac 
tromethamine
600–800 mg every 6–8 hours for no 
more than 5 days
30 mg intramuscularly every 6 
hours for no more than 5 days
Abdominal cramps Dicyclomine 10 mg every 6 hours
Nausea or vomiting Prochlorperazine
Ondansetron
10 mg intramuscularly 3 times a day
8 mg orally every 8 hours
Diarrhoea Loperamide 4 mg initially, then 2 mg after each 
stool
1.2.1.7 Post-detoxification care and treatment
All patients completing detoxification must be connected to after-
care psychosocial support services. Following the acute withdrawal 
phase, protracted withdrawal can last for a few months. This phase 
is characterised by significant craving for the preferred opioid and a 
diminished sense of well-being. Relapse is extremely common following 
detoxification in those not provided adequate psychosocial support.
Those with moderate to severe opioid dependency and a history of 
injecting should be considered for opioid substitution therapy with 
methadone or buprenorphine.
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1.2.1.8 Special issues in opioid withdrawal
Management of withdrawal from poly-drug use
A person using three or more substances (excluding caffeine and 
nicotine) and meeting the criteria for dependence is a poly-drug-
dependent user. Additional sedative–hypnotic dependence can lead to 
serious hazards, including seizures, toxic psychosis, hyperthermia and 
even death. Withdrawal from stimulant drugs is much less of a physical 
hazard, though it is associated with severe depression and suicide. 
Depending on the nature and extent of the withdrawal symptoms, 
appropriate treatment should be instituted. If sedative–hypnotic 
dependence is present, it may be preferable to maintain the patient 
on methadone or buprenorphine, withdraw the sedative gradually, and 
finally withdraw the methadone or buprenorphine.
Seizures
Opioid intoxication and withdrawal do not cause seizures. However, 
seizures can occur with the chronic use of propoxyphene. Often, a 
seizure signifies undiagnosed sedative–hypnotic withdrawal, stimulant 
intoxication or another medical condition (e.g. epilepsy or head injury). 
Immediate removal to hospital is recommended in case a patient 
presents with seizures.
Medical conditions
When serious medical or surgical conditions are present, withdrawal 
should be delayed or done very gradually to minimise stress.
Pregnancy
Withdrawal is not recommended during pregnancy. Methadone 
maintenance therapy is accepted as standard for a pregnant woman 
dependent on heroin. The need for increased dosage because of 
quickened metabolism can be handled by splitting the dose of 
methadone during the day. Buprenorphine maintenance is also 
effective. Pregnancy can be a strong motivator for giving up drug 
misuse. Every pregnant woman attending the service site should be 
Section 1 31Section 1
referred for specialist opinion and counselling, as opting for total 
withdrawal and abstinence can be complicated.
1.2.2 Management of withdrawal from amphetamine-type 
stimulants (ATS)
The withdrawal syndrome from ATS use may mimic intoxication. Symptoms of 
depression and associated suicidal ideation may complicate ATS withdrawal.
1.2.2.1 Clinical features
People dependent on CNS-depressant drugs such as opioids and 
alcohol suffer withdrawal symptoms that are the opposite of the acute 
pharmacological effects of these drugs. In contrast, several features of 
ATS withdrawal mimic those of intoxication.
Table 8 Comparison of the features of ATS withdrawal and intoxication
ATS intoxication ATS withdrawal
Increased confidence
Anxiety
Agitation
Motor hyperactivity
Sleep disturbance
Excitement
Rapid speech
Irritability
Hyper vigilance
Muscle twitches
Hand tremors
Sweating
Rapid heart rate
Raised blood pressure
Dilated pupils
Increased body temperature
Dry mouth
Jaw clenching
(Psychosis, hyperthermia and seizures 
are features of toxicity.)
The initial ‘crash’ period (excessive 
sleeping, eating and irritability) followed 
by the withdrawal syndrome:
Dysphoria (distressed mood)
Depression
Slowing of physical movements
Poor concentration
Agitation
Sleep disturbance
Irritability
Lethargy
Exhaustion
Craving to use ATS
Anxiety
Variable appetite
Anhedonia (lack of interest in pleasurable 
activities)
(Some symptoms of methamphetamine 
withdrawal may last for many months.)
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The severity of withdrawal symptoms is influenced by the following:
•	 severity of dependence
•	 duration of use
•	 frequency of ATS use
•	 potency of the ATS used
•	 duration of action of the ATS consumed
•	 route of administration
•	 presence of other psychiatric disorders
•	 presence of other medical disorders
•	 physical environment in which withdrawal occurs
•	 fears and expectations about withdrawal.
1.2.2.2 ATS Detoxification
General principles
•	 Supervised detoxification ensures that withdrawal symptoms and 
attendant risks are minimised.
•	 Detoxification as a stand alone process has little value.
•	 Rates of relapse following detoxification from ATS are high.
•	 Psychosocial interventions are an extremely important component 
of post-detoxification treatment for ATS dependence
Assessment for detoxification
Drug-use history:
•	 Amount of ATS used.
•	 Type of ATS used.
•	 Route of administration (e.g. inhalation, intranasal, oral or injected).
•	 Frequency of use (e.g. irregular binges or regular daily use).
•	 Duration of use.
•	 Use of other drugs including alcohol, benzodiazepines and opioids.
•	 Dependence on ATS (are the criteria for dependence met?).
•	 Dependence on other drugs and/or alcohol (are the criteria for 
dependence met?).
•	 Experience of previous detoxification attempts, withdrawal 
symptoms, severity, course and outcome.
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Other conditions:
•	 Concomitant illnesses (HIV infection, hepatitis B or C infection, 
tuberculosis, etc.).
•	 Concomitant psychiatric disorders or psychiatric symptoms 
(depression, paranoia, psychosis, suicidal ideation, etc.).
Other factors:
•	 Reasons for seeking treatment
•	 Availability of family support
•	 Availability of social support
•	 Employment status
•	 Presence of legal problems
•	 Availability of stable accommodation
•	 Patient’s understanding of withdrawal
•	 Expectation from treatment
Outpatient detoxification: During outpatient detoxification, the person 
is regularly supervised at the service site by a nurse or doctor. The 
criteria for outpatient detoxification are as follows:
•	 no previous history of complicated withdrawal
•	 no severe withdrawal
•	 no concomitant medical or psychiatric illness that cannot be 
managed as an outpatient
•	 a stable home environment.
There is no evidence that tapered withdrawal from ATS is preferable to abrupt 
cessation.
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1.2.2.3 Treatment interventions
Specific pharmacotherapies such as antidepressants, antipsychotics and 
benzodiazepines are effective for the concurrent management of specific 
co-morbid symptoms. 
Antidepressants
Antidepressants have limited benefit in the treatment of amphetamine 
dependence but are suitable for managing concurrent depression. 
Antidepressants have side-effects, and may have a lag period of 4–6 weeks 
for onset of action. When ATS is taken together with antidepressants, 
there is an increased risk for serotonin toxicity. Warning: Fluoxetine may 
potentiate the effects of cocaine (see section 2.3.2.)
Anxiolytics
Anxiety that requires special attention during management is often a 
feature of ATS withdrawal. Benzodiazepines (preferably diazepam as it 
is long-acting) are indicated for managing anxiety or to initiate sleep in 
early withdrawal. They should be prescribed for a maximum of 2 weeks 
and preferably dispensed daily.
Antipsychotics
If psychotic symptoms become manifest, antipsychotic medications 
such as haloperidol or chlorpromazine—or second-generation 
antipsychotics such as risperidone, olanzapine, quetiapine, aripiprazole 
and amisulpride, depending upon local availability—may be prescribed 
in the short term, up to 2 weeks. If psychosis persists, a specialist needs 
to carry out a psychiatric evaluation.
Psychological therapies
Any psychological or supportive therapy aims to help the person safely 
complete withdrawal and engage in post-detoxification management. 
As fear of withdrawal is a key obstacle for those completing 
detoxification, it is necessary for them to be prepared for this process 
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and be reassured of a safe and comfortable withdrawal process. Patient 
education and ongoing support from the team members at the service 
site is vital. If outpatient detoxification is being provided then family 
members and friends of the patients should also be educated.
Brief interventions: Brief, opportunistic interventions focused 
on motivation should be offered to people who use ATS. These 
interventions should aim to increase motivation to change behaviour 
and provide non-judgmental feedback.
Self-help groups: Provide people who misuse drugs with information 
about local self-help and support groups.
Relapse following detoxification is common.
1.2.3 Management of alcohol withdrawal
The management of alcohol withdrawal requires thorough awareness of any 
illness afflicting the patient, the careful selection of pharmacological agents, 
education and reassurance.
Table 9 Recognition of alcohol withdrawal symptoms
Tremors of the extended hands, 
tongue or eyelids Fever
Sweating Decreased attention
Nausea or vomiting Disorientation
Tachycardia (rapid heart rate) Clouding of consciousness
Psychomotor agitation
Hallucinations that may be visual, tactile 
or auditory
Sleep disturbance Withdrawal seizures or fits
Anxiety Delirium
Headache
Patients will often complain of withdrawal symptoms but may not have 
objective evidence of withdrawal.
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1.2.3.1 Basic assessment for alcohol withdrawal    
•	 History, including history of previous episodes of alcohol 
withdrawal
•	 Physical examination
•	 Time of most recent drink
•	 Concomitant intake of illicit and prescribed drugs
•	 Severity of withdrawal symptoms
•	 Coexisting medical or psychiatric disorders
Diagnosis of alcohol withdrawal syndrome
Alcohol withdrawal syndrome is common when heavy or prolonged 
use is suddenly stopped or reduced. Diagnosis requires that two or 
more of the following symptoms are present:
•	 autonomic hyperactivity (e.g. sweating or pulse rate higher than 100 
beats per minute)
•	 increased hand tremors
•	 insomnia
•	 nausea or vomiting
•	 transient visual, tactile or auditory hallucinations or illusions
•	 psychomotor agitation
•	 anxiety
•	 seizures.
Significance of alcohol withdrawal syndrome
Alcohol withdrawal syndrome is a common medical problem. Mortality 
in alcohol withdrawal can be as high as 15%. Outpatient withdrawal for 
heavy alcohol users is not recommended.
Whereas mild-to-moderate symptoms of alcohol withdrawal can be managed 
on an outpatient basis at the service site, severe symptoms such as seizures or 
delirium need to be treated in a hospital.
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1.2.3.2 Management of alcohol withdrawal syndrome 
The aims of detoxification are as follows:
•	 provide safe withdrawal from alcohol and enable the patient to 
become alcohol free.
•	 provide withdrawal that is humane, thus protecting the patient’s 
dignity and minimising discomfort.
•	 prepare the patient for ongoing treatment of dependence on 
alcohol.
Key issues in alcohol detoxification:
•	 Conduct a thorough physical examination, as physical illness 
markedly increases the risk of convulsions or delirium.
•	 During detoxification, avoid intravenous fluids unless there are 
medical indications for them.
•	 Provide education and reassurance, as they are extremely 
important.
•	 The patient’s symptoms are likely to markedly diminish with any 
CNS depressant such as any benzodiazepine in adequate doses.
•	 Withdrawal treatment does not usually require an anticonvulsant 
unless the patient has seizures.
Medications used to manage alcohol withdrawal
The ideal drug for managing alcohol withdrawal should:
•	 have few significant side-effects
•	 have a wide margin of safety
•	 not depend on liver function for its metabolism
•	 not have potential for abuse.
Benzodiazepines (the main drugs used in alcohol detoxification)
Longer-acting benzodiazepines (e.g. diazepam and chlordiazepoxide) 
may be more effective than shorter-acting ones at preventing seizures. 
They may produce a smoother withdrawal course with less breakthrough 
or rebound symptoms than shorter-acting agents. Drugs with a rapid 
onset of action may have a higher abuse potential than those with a 
slower onset of action.
Section 1Section 138
Benzodiazepines can be given in a number of ways:
•	 in ‘front loading’, a loading dose is followed by doses every 90 
minutes or so to achieve light sedation.
•	 symptom-triggered therapy for patients without a history of 
complications.
•	 a tapering dose regimen (Table 10).
Table 10 Treatment of alcohol withdrawal: Chlordiazepoxide* regimen
Day Dose
1 20 mg 4 times
2 15 mg 4 times
3 10 mg 4 times
4 5 mg 4 times
5 5 mg twice
6 5 mg at bedtime
7 Stop
* Chlordiazepoxide 15 mg = diazepam 5 mg = oxazepam 15 mg (approximately).
When administering benzodiazepines, bear the following in mind:
•	 Observe the patient at regular intervals.
•	 Check the pulse and blood pressure regularly.
•	 Many clinicians prefer diazepam for those with a history of seizures.
•	 Oxazepam may be preferable to benzodiazepine for some patients 
who show abnormal liver function or who have chronic liver disease.
Thiamine
As alcohol interferes with the absorption of the B group of vitamins, all 
patients should receive vitamins orally including thiamine (which is not 
stored well in the body) at a dose of 100 mg twice daily. Thiamine is one 
of the essential vitamins which helps in glucose metabolism directly. 
In an alcohol withdrawal state if glucose is not metabolised properly 
the brain gets affected badly which in turn increases the chance of 
Korsakoff’s psychosis. When Wernicke encephalopathy or Korsakoff’s 
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psychosis is suspected, prophylactic parenteral administration of B 
vitamins is appropriate. IM/IV (intramuscular/intravenous) ampoules 
of highly potent vitamin B complex containing at least 200–300 mg 
of thiamine should be given daily for 3–5 days. This is an absolute 
minimum regimen that should be replaced after 5 days by oral thiamine 
100 mg twice daily. 
Antipsychotics
Patients who continue to show psychotic symptoms such 
as hallucinations or delusions despite appropriate doses of 
benzodiazepines should be given haloperidol 5 mg orally or IM 
(rarely IV) and the dose repeated once, if needed. Caution is required 
because haloperidol can worsen the risk of seizures. Parenteral 
procyclidine or oral procyclidine or trihexyphenidyl should be 
available for extrapyramidal syndrome and dystonic reaction.
β-adrenoceptor-blocking drugs reduce the autonomic features of 
withdrawal but have no anticonvulsant activity and are known to cause 
delirium.
Clonidine ameliorates mild-to-moderate withdrawal but is not effective 
in preventing seizures or delirium.
Table 11 Symptomatic therapy in alcohol withdrawal syndrome
Symptom Treatment
Dehydration Ensure adequate fluid intake to maintain hydration 
and electrolyte balance. Dehydration can cause 
cardiac arrhythmia and death.
Pain Paracetamol 0.5–1.0 grams every 4–6 hours to a 
maximum of 4 grams daily 
Nausea and vomiting Metoclopromide 10 mg or prochlorperazine 5 mg 
4–6 hourly
Diarrhoea Diphenoxylate and atropine (trade name Lomotil), 
loperamide
Itchy skin (occurs commonly 
and not only in individuals 
with alcoholic liver disease)
Antihistamines 
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Flexible regimen to treat alcohol withdrawal
Patients should be treated with patient-specific and flexible regimens 
that respond to changes in the severity of the withdrawal symptoms 
triggered. Fixed treatment schedules, in which the patient is given a 
standard regimen irrespective of symptoms, are inappropriate.
The Clinical Institute Withdrawal Assessment for Alcohol—Revised 
(CIWA-Ar) scale is a validated 10-item assessment tool that can be 
used to quantify the severity of alcohol withdrawal syndrome and 
to monitor and medicate patients going through withdrawal (see 
appendix 2). Treatment should be initiated using a symptom-triggered 
regimen when the CIWA-Ar score is >8, as this will benefit the patient 
symptomatically. When the CIWA-Ar score is ≥15, using a symptom-
triggered regimen reduces the risk of developing major complications.
Table 12 Managing alcohol withdrawal using the revised Clinical 
Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale
CIWA-Ar score Management
All patients irrespective of score Thiamine 100 mg IM, then thiamine 100 mg 
orally twice daily for 3 days
>0 but <8
Vital signs are stable
No medication; repeat vital signs every 4 
hours and the CIWA every 8 hours
>8 but <15 Lorazepam 2 mg orally or IM and repeat vital 
signs every 2 hours and the CIWA every 4 hours
>15 or diastolic blood pressure 
>110 mmHg
Lorazepam 2 mg orally or intramuscularly 
every hour until patient has a CIWA of <15 or 
diastolic blood pressure <110 mmHg (CIWA- 
and vital signs checked every hour until 
patient’s CIWA is <15 and diastolic blood 
pressure <110 mmHg)
Call physician if patient requires >6 mg of 
lorazepam in 3 hours
Wait until CIWA is <8 for 3 consecutive 8-hour 
increments
It may be necessary to wake up the patient to record vital signs and 
complete the CIWA-Ar.
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1.2.4 Management of benzodiazepine withdrawal
Patients who become physically dependent on benzodiazepines are usually 
either poly-drug users of heroin, ATS such as methamphetamine and alcohol or 
patients who have been prescribed benzodiazepines without proper supervision 
and monitoring.
1.2.4.1 Benzodiazepine misuse
Benzodiazepines are sedative–hypnotics prescribed to ameliorate 
anxiety, panic and insomnia. Although benzodiazepines are relatively 
safe when taken alone even in doses over the safety limit, the potential 
for death markedly increases in combination with alcohol or other 
sedative–hypnotics. In combination with opioids that are used for 
treatment such as methadone or buprenorphine, they contribute to an 
increased risk of mortality from overdose.
While many people who are prescribed benzodiazepines may not find 
their effects pleasurable or reinforcing, alcohol and prescription drug 
users may be vulnerable to benzodiazepine dependency. Street drug 
users may take benzodiazepines for the following reasons:
•	 to ameliorate the adverse effects of methamphetamine.
•	 to self-medicate for heroin or alcohol withdrawal.
•	 to enhance the effect of an opioid such as methadone or 
buprenorphine.
•	 to get high when preferred drugs are unavailable.
1.2.4.2 Signs and symptoms of benzodiazepine (sedative–hypnotic) 
withdrawal
•	 Anxiety •	 Anorexia (loss of appetite)
•	 Tremors •	 Nausea
•	 Nightmares •	 Vomiting
•	 Hyperpyrexia (increased 
body temperature)
•	 Delirium
•	 Postural hypotension  
(significant reduction in blood 
pressure due to postural changes)
•	 Seizures
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Abruptly discontinuing benzodiazepines to patients who are physically 
dependent on them can have serious adverse medical consequences, 
including death. With short-acting benzodiazepines (e.g. oxazepam, 
alprazolam and triazolam), withdrawal symptoms typically begin 12–24 
hours after the last dose and peak in intensity between 24 and 72 hours. 
Symptoms may develop slowly in people with liver disease and the 
elderly because of slow drug metabolism. With long-acting drugs such 
as diazepam and chlordiazepoxide, withdrawal symptoms peak after 
5–8 days.
Table 13 Characteristics of benzodiazepine withdrawal syndrome
Withdrawal 
syndrome
Signs and symptoms Time course
Re-emergence of 
symptoms
Recurrence of the 
same symptoms 
present before taking 
benzodiazepines (e.g. 
anxiety and insomnia)
Symptoms emerge on 
stopping benzodiazepines and 
continue unabated over time
Symptoms rebound Same symptoms that 
were present before 
taking benzodiazepines
Begins 1–2 days after stopping 
short-acting benzodiazepines 
and 3–8 days after stopping 
long-acting benzodiazepines, 
lasting 7–14 days
Protracted low-dose 
withdrawal
Anxiety, agitation, 
tachycardia, anorexia, 
blurred vision, muscle 
cramps, insomnia, 
nightmares, confusion, 
muscle spasms, 
psychosis, increased 
sensitivity to sounds and 
light, and paraesthesia
Signs and symptoms 
emerge 1–7 days after a 
benzodiazepine is stopped
High-dose 
withdrawal
Anxiety, insomnia, 
nightmares, seizures, 
psychosis, hyperpyrexia 
and death
Starts 1–2 days after stopping 
short-acting benzodiazepines 
and 3–8 days after stopping 
long-acting benzodiazepines
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1.2.4.3 Management of benzodiazepine withdrawal
People dependent on benzodiazepines should be regularly monitored 
for symptoms and complications. As withdrawal symptoms can 
fluctuate rapidly, health workers must communicate regularly with the 
person about them. Patient education and reassurance are necessary.
The safest way to manage benzodiazepine withdrawal is to gradually 
reduce the dose. To stabilise the person, an appropriate dose of 
diazepam needs to be given. The calculated dose of diazepam is 
provided in divided doses to the patient. There has to be at least a week 
between dose reductions to make withdrawal safe and comfortable.
Table 14 Equivalent doses of benzodiazepines for 5 mg diazepam
Drug Dose
Triazolam 0.25 mg
Alprazolam 0.50 mg
Lorazepam 0.50 mg
Flunitrazepam 1.00 mg
Midazolam 2.50 mg
Nitrazepam 5.00 mg
Clonazepam 1.00 mg
Temazepam 10.00 mg
Oxazepam 15.00 mg
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Table 15 Benzodiazepine dose-reduction schedule (>50 mg/day 
diazepam equivalent)
Reducing doses* Daily dose
Starting dose 15.0 mg (5.0 mg 3 times daily)
First reduction 12.5 mg 3 times daily (5.0 mg, 2.5 mg, 5.0 mg)
Second reduction 10.0 mg twice daily (5.0 mg, 5.0 mg)
Third reduction 7.5 mg twice daily (2.5 mg, 5.0 mg)
Fourth reduction 5.0 mg (once at night)
Fifth reduction 2.5 mg (once at night)
* The interval between dose reductions should be at least 1 week.
Table 16 Benzodiazepine dose-reduction schedule (<50 mg/day 
diazepam equivalent)
Reducing doses* Daily dose
Starting dose 40 mg (10 mg four times daily)
First reduction 30 mg 4 times daily (10 mg, 5 mg, 5 mg, 10 mg)
Second reduction 20 mg 3 times daily (5 mg, 5 mg, 10 mg)
Third reduction 10 mg (once at night)
Fourth reduction 5 mg (once at night)
* The interval between dose reductions should be at least 1 week.
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1.2.5 Management of tobacco withdrawal
Tobacco is the leading avoidable cause of disease, accounting for massive 
death and morbidity. Tobacco cessation interventions can be beneficial and 
cost-effective for the tobacco user.
1.2.5.1 Nicotine withdrawal syndrome
Nicotine is highly dependence-inducing, and nicotine-dependent 
individuals experience withdrawal symptoms on abstinence. The 
tobacco withdrawal syndrome is characterised by the following:
•	 depressed mood
•	 insomnia
•	 irritability, frustration and anger
•	 anxiety
•	 difficulty in concentration
•	 restlessness
•	 decreased heart rate
•	 increased appetite or weight gain.
These withdrawal symptoms cause distress in individuals who quit 
tobacco. Nicotine withdrawal symptoms typically resolve over 10–14 
days but can last for up to a month. Associations that trigger thoughts 
about smoking can persist for several years.
Smoking cessation for tobacco users
Assess
Health workers should base their approach on an assessment of the 
person’s current readiness to change. For example, if a person using 
drugs has already decided to quit smoking, helping them implement 
the decision is useful; however, if the patient is not convinced of the 
reasons for quitting, then health workers should address this first, 
rather than advising on ways of trying to quit. Increasing the motivation 
to stop smoking can be done through motivational interviews. Special 
counselling sessions by trained health workers can assess and address 
motivation, readiness to change and self-efficacy in stopping smoking.
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Advise
Smoking tobacco is extremely common among people who use drugs, 
and it is a challenge to help users quit. At every opportunity, health 
workers should encourage users to give up smoking. As health workers 
establish good rapport with people who use drugs, they should advise 
users to stop using tobacco in a sensitive way. Simple advice from the 
doctor treating the person increases the chances of stopping use. 
In addition, all people attempting to quit must receive support and 
encouragement. Advice on stopping smoking should be offered during 
routine consultations with persons using drugs. All health workers play 
an important role in this.
Assist
Behavioural coping strategies are helpful and they include the 4 Ds.
•	 Delay acting on the desire and urge to smoke
•	 Deep breathe and repeat at least three times
•	 Drink water slowly
•	 Do something else to take the mind off smoking.
Medications to facilitate smoking cessation: Nicotine replacement 
therapy (NRT) and bupropion (an antidepressant), varenicline (a 
partial agonist binding with high affinity to the alpha4 beta2 nicotinic 
acetylcholine receptor) are recommended for tobacco-dependent 
smokers who express a desire to quit and feel they need pharmacological 
help or who have a history of multiple failed attempts to quit.
NRT preparations and dose: All NRTs should be used for about 8–12 
weeks but may be continued longer, if needed, to prevent relapse. 
They can be used in combination if required, usually a patch plus a 
faster-acting oral NRT, for relief of situational urges to smoke.
•	 Gum (2 mg or 4 mg) is chewed slowly when the urge to smoke 
occurs, up to a maximum of 15 pieces daily. The gum needs to rest 
against the gums or buccal mucosa for absorption to occur.
•	 Patches come in two different types, 24 hour or 16 hour, with no 
difference in efficacy. Sixteen-hour patches (25 mg, 15 mg, 10 mg and 
5 mg) are removed at bedtime, while 24-hour patches (21 mg, 14 mg 
and 7 mg) are worn throughout the night and replaced in the morning.
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In many countries, the following are also used as NRT:
•	 sublingual tablet of nicotine (2 mg): recommended dose 1 tablet/
hour or, for heavy smokers of more than 20 cigarettes/day, 2 
tablets/hour.
•	 nasal spray: each metered spray delivers 0.5 mg of nicotine, with 
a dose being one spray to each nostril and administered up to 
twice per hour, or 32 doses per day; this is most suitable for highly 
dependent smokers.
•	 inhaler: 10 mg/cartridge used with a plastic mouth piece., with 
dosage initially up to 12 cartridges/day, puffed for 20 minutes 
every hour.
•	 lozenge (1 mg, 2 mg and 4 mg): up to 15/day and, like the chewing 
gum, needs to be rested against the buccal mucosa.
Bupropion: Start 1–2 weeks before the planned quit date at 150 mg 
daily for 6 days, then 150 mg twice daily for a maximum of 2 months.
Side-effects of bupropion: These are insomnia, dry mouth, headache, 
hypersensitivity and rash. The risk of seizure is about 1 in 1000. 
Bupropion is contraindicated with eating disorders, CNS tumours, 
bipolar disorder, pregnancy, breastfeeding, age below 18 years, and 
acute benzodiazepine or alcohol withdrawal.
Table 17 Varenicline in tobacco cessation
Period Dose
Days 1–3 0.5 mg orally
Days 4–7 0.5 mg twice daily
Day 8–end of week 12 1.0 mg twice daily
If successful after 12 weeks, the next 
12 weeks
1.0 mg daily may be continued as 
maintenance treatment
Smokers should set a quit date between days 8 and 14 of starting to 
take varenicline.
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Arrange
It is necessary to arrange supportive social networks and follow up with 
those who are quitting smoking, as these interventions improve the 
likelihood of abstinence from tobacco. Advice on relapse prevention 
and coping strategies to handle high-risk situations are effective in 
preventing relapse.
1.3 Management of intoxication
1.3.1 Opioid intoxication
A triad of symptoms is typical of opioid overdose: pinpoint pupils, respiratory 
depression and CNS depression.
Figure 5 Symptoms of opioid intoxication and overdose (stages of 
exacerbation)
Harmful use 
Brief interventions in generalist settings 
(including drop-in centres)
 
None
Public health programmes—primary prevention 
Hazardous use 
Simple brief interventions in generalist settings 
(including drop-in centres) 
Moderately 
dependent use 
 
Less intensive intervention
in generalist settings 
 
Severe 
dependence*
Heroin
1E-8
1E-7
1E-6
1E-5
0 5 10 15 20
Hours
P
la
sm
ic
 le
ve
ls
 (M
)
P
la
sm
ic
 le
ve
ls
 (M
)
Hours
Methadone
1E-8
1E-7
1E-6
1E-5
0 5 10 15 20
Withdrawal
Normal
Euphoria
Withdrawal
Normal
Euphoria
Treatm
ent plan
Di
ag
no
sis
Screening
Assessment
Psychosocial servicesM
ed
ica
l c
ar
e,
 in
clu
di
ng
 fo
r 
se
xu
al
ly 
tra
ns
m
itt
ed
 in
fe
ct
io
s
Withdrawal services
Detox
services
Pinpoint pupils
Slurred speech
Unsteady gait
Poor balance
Drowsiness
Slowed movement
Coma
Pinpoint pupils
Respiratory
depression
Hypoxia and
death
Service site:
Assessment
Withdrawal and 
intoxication 
management
Primary medical care
Primary mental health care
Harm reduction services
Referral 
services to 
drug 
dependence 
treatment
Referral to 
ART therapy, TB, 
and voluntary 
counselling and 
testing services 
Referral 
services to 
other 
medical 
services
1.3.1.1 Facts about overdose
•	 High purity of heroin is seldom the cause of a fatal overdose.
•	 The mixing of heroin, alcohol and benzodiazepines is the most 
common cause of fatal overdose.
•	 Death from overdose often occurs several hours after heroin is taken.
•	 Death from overdose is less common among new or inexperienced users.
•	 Interventions are possible, as many cases of overdose are 
witnessed by others.
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Risk factors for overdose-related morbidity
•	 Old age
•	 Male gender
•	 Long history of drug use
•	 Injecting alone
•	 Poly-substance use
•	 Previous history of overdose.
After voluntary or involuntary cessation of opioids the physical, 
tolerance for opioids decreases. When people relapse and use the 
same quantity that they used earlier, it often results in overdose. 
Similarly, substance users who have been released after prolonged 
incarceration who go back to using are at high risk of overdose. The 
strength, quality and purity of heroin also varies considerably, and those 
using the drug without testing it are in greater danger of overdose. 
Mixing benzodiazepine and opioids, and mixing alcohol and opioids, 
may cause an overdose. Sometimes factors unrelated to drug use such 
as poor health and depression can also contribute to overdoses.
Preventing overdose
•	 Avoid mixing drugs.
•	 Drug users should have good knowledge about the effects of the 
specific drugs they are taking. They should be educated in simple 
language about the pros and cons of drug misuse with a specific 
focus on overdose.
•	 Test small amounts of drugs of unknown quality first.
•	 Use a smaller amount of drugs if they have not been used lately, 
and beware of lowered tolerance.
•	 Try to use drugs with a friend rather than alone.
•	 Try not to take too much too quickly.
•	 Use less if sick or recovering from an illness.
•	 Use the drug in a way that gets a slower high (e.g. snorting heroin 
instead of injecting).
•	 Use with someone who knows what to do in case of overdose.
•	 Wait to experience the effects of the drugs before using more.
•	 Buy from a regular source that can be trusted.
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•	 Keep track of how much one has used.
•	 Do not use regular dose if you have come recently out of 
detoxification, rehabilitation or prison.
1.3.1.2 Management of opioid intoxication
Warning signs
•	 The person appears asleep or unconscious.
•	 The face or lips appear pale or blue.
•	 The person has trouble breathing or breathing is very slow.
Assessment of consciousness
•	 See if the person can open his or her eyes and respond to his or 
her name.
•	 Test response to pain by rubbing the chest with the knuckles or 
pressing hard with a pencil in the space between the fingers.
•	 If possible, ask the person to get up and walk.
•	 If the person feels sick, has tightness of the chest or is short of 
breath, seek help immediately.
•	 Detect respiratory depression in opioid overdose, by noting 
respiratory arrest with slow/undetectable pulse, pinpoint pupils 
unreactive to light, and snoring giving way to shallow respiration 
(eight or less breaths per minute).
Managing a person who has stopped breathing
Step 1
•	 Check to see if the person’s airway is clear.
•	 If something is blocking the airway, make the person lie down 
on his or her side, clear the mouth and airway of food or vomit . 
This is best done by pulling the chin down with one hand while 
simultaneously tilting the head of the patient backwards. Use the 
other hand to reach into the mouth and clear any foreign objects or 
blockages.
•	 Once the airway is clear, roll the person gently onto his or her back.
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Step 2
•	 Look at the chest and check for rise and fall. Listen and feel for 
breathing. Take no more than 10 seconds to do this. If no breathing 
is detectable, give mouth to mouth breathing support.
Step 3
•	 Tilt the head back and pinch the nose shut.
•	 Take a breath, then seal your lips around the person’s mouth.
•	 Give two initial breaths.
•	 Visualise the centre of the chest and compress at that point with 
straight arms locked at the elbow.
•	 Maintain a compression–ventilation ratio of 30 compressions to 2 
ventilations (press 30 times followed by two breaths).
•	 Do not deliver compressions fast and hard; avoid over ventilation 
(i.e. more than two breaths for every 30 compressions).
Shift the person to a hospital as soon as possible in an ambulance. 
All health workers and outreach workers must be trained in 
cardiopulmonary resuscitation.
In addition Naloxone should be available at DICs, methadone clinics 
and township and county level hospitals. Where possible, outreach 
workers should also be trained (in addition to health staff) to provide 
Naloxone injections to reverse opioid overdose.
What is Naloxone?
 – A pure opioid antagonist.
 – Highly effective at reversing opioid overdose.
 – Safe and with essentially no side-effects except may induce 
withdrawal symptoms.
 – Available in liquid form, usually 0.4 mg/ml.
 – May be administered by intramuscular, subcutaneous or 
intravenous injection, or intranasally with an aerator.
Naloxone administration steps:
 – prepare an intramuscular syringe ( with a long needle if 
possible) and draw up 1-2ml of naloxone.
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 – Gently push the plunger to release any air bubbles before 
injecting.
 – Inject into a large muscle such as upper arm, buttocks or thigh 
(if possible, swab the area first).
 – there is no need to inject Naloxone into a vein – intramuscular 
injection is effective.
After administering Naloxone
 – Naloxone takes effect in 1-3 minutes.
 – Continue rescue breathing and supporting the person until it does.
 – Re-administer naloxone if first dose is not effective.
 – If multiple naloxone doses don’t revive someone, it’s probably 
something other than an opioid overdose causing the problem: 
call for help immediately if you haven’t done so already.
Naloxone will usually wear off in 30-90 minutes. It is not wise to leave a 
person who has overdosed alone even if they seem awake and fine after 
the injection as sedation may return after the effect of Naloxone wears 
off. It is also often the case that withdrawal will set in. It is important 
to reassure the person that the naloxone will wear off soon and they 
should not use more drugs to feel better.
1.3.2 ATS intoxication
The skilful management of manifestations of ATS toxicity requires accurate 
assessment, a safe environment, careful monitoring and a prompt response.
1.3.2.1 Assessment
Important questions that should be asked if ATS use is suspected are:
•	 Have you taken drugs such as yaba or yama?
•	 When did you take them last?
•	 What other drugs have you taken along with yaba or yama?
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Suspect problems with ATS use if the person is:
•	 severely agitated
•	 difficult to calm
•	 suspicious or paranoid
•	 acting impulsively
•	 easily startled
•	 out of touch with reality.
Suspect ATS use also if the person has:
•	 dilated (big) pupils
•	 increased sweating
•	 severe headache
•	 high temperature
•	 rapid breathing
•	 body stiffness or rigid limbs.
1.3.2.2 Management
Uncomplicated intoxication may require observation at the service site and 
monitoring for several hours. Management is supportive; the use of sedation 
for managing acute behavioural disturbances and severe psychotic symptoms 
may be required.
Communicating with people with suspected ATS intoxication
•	 Personalise the interaction with the person, using his or her first 
name, if known.
•	 Offer calming communication in a private space if possible; 
question and interact with the person in a calm way to de-escalate 
potentially aggressive interaction.
•	 Preferably ask open-ended questions to elicit information from 
the person.
•	 Even if the person is hostile or aggressive, communicate with him 
or her in a consistently even tone of voice.
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•	 Avoid using terms that may provoke or prompt an aggressive 
outburst.
•	 Avoid sustained eye contact, as this may provoke individuals who 
are suspicious or paranoid.
•	 Prompt medical assistance such as sedation will avoid any need to 
restrain individuals.
Indicators of medical emergency requiring treatment in a hospital
•	 Fits
•	 Rigidity
•	 Rapidly escalating body temperature
•	 Chest pain
•	 Alteration in levels of consciousness
•	 Uncontrolled blood pressure
•	 Severe headache
•	 Severe agitation
Managing acute behavioural disturbance in substance users
General principles of using sedative drugs
•	 Non-specific sedation is required for managing acutely agitated or 
violent people.
•	 The ideal medication should possess a rapid sedative action, 
providing quick control of violent behaviour.
•	 Sedation should be given to the point of rousable sleep, not 
unconsciousness; over-sedation should be avoided.
Benzodiazepines
•	 These are the drugs of choice, as they are safer than antipsychotics.
•	 They exert benefits in cases with serotonin toxicity (see immediately 
below) and agitation.
•	 They are the first line of treatment for cardiac toxicity associated 
with ATS use.
•	 Among benzodiazepines, lorazepam may be the best choice 
because it is as effective as haloperidol in controlling agitation and 
can be administered IM.
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Typical antipsychotics
•	 Haloperidol is frequently used for sedation.
•	 Compared with other typical antipsychotics, it causes less 
hypotension, fewer anticholinergic side-effects and less of a seizure 
threshold decline.
•	 It can be administered orally, IM or IV.
•	 One disadvantage is that haloperidol is not the most sedating 
of neuroleptics and so may not be appropriate for emergency 
sedation.
•	 The other disadvantage is that it may cause extrapyramidal symptoms 
such as acute dystonia (see appendix 4 and section 2.3.5).
Combination regimens
A combination of lorazepam (2 mg IM) and haloperidol (5 mg IM) is 
used, as this may be more efficacious than single agents. Patients 
receiving this combination report fewer extrapyramidal symptoms.
Serotonin toxicity
Serotonin toxicity may occur after ATS ingestion alone or if taken 
together with other serotonergic drugs such as antidepressants.
Diagnosis
The presence of at least three of the following symptoms along with a 
history of recent serotonergic drug use should alert the health worker 
to the possibility of serotonin toxicity:
•	 altered mental status  
(confusion, hypomania)
•	 agitation
•	 tremors
•	 shivering
•	 diarrhoea
•	 hyperreflexia
•	 myoclonic jerks
•	 ataxia
•	 fever
•	 diaphoresis (excessive sweating)
•	 convulsions
•	 multiple organ failure
•	 death (if poorly managed).
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Well-defined clinical features such as clonus, agitation, diaphoresis, 
tremors, hyperreflexia, hypertonia and fever are sensitive and specific 
for serotonin toxicity.
Managing serotonin toxicity
•	 Provide prompt supportive care including cooling blankets and fans.
•	 Discontinue all serotonergic drugs, including sympathomimetics 
such as amphetamines and methamphetamines.
•	 Chlorpromazine may have a role in management, but rule 
out neuroleptic malignant syndrome before administering 
chlorpromazine.
•	 Benzodiazepines may help reduce muscle rigidity, agitation and 
seizures. The drug of choice is lorazepam (1–2 mg by slow IV 
injection every 30 minutes until adequate sedation occurs).
•	 Cyproheptadine 4–8 mg up to 10–20 mg orally, repeated every 2–4 
hours up to a maximum of 0.5 mg/day per kilogram of body weight 
has been claimed to be the best antiserotonergic drug strategy. 
Beware of urinary retention.
•	 Mirtazapine may reduce serotonin toxicity.
•	 Nitroglycerine 2 mg/minute per kilogram of body weight has been 
reported to rapidly relieve severe serotonin syndrome.
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1.4 Other services including referrals for people using drugs
People who use drugs have multiple requirements that need to be addressed. 
If a menu of options for drug dependence treatment is available, it will help 
people who use drugs to choose from the various options and improve their 
health and quality of life.
Figure 6 Referral services at the service site
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Apart from assessing and managing withdrawal and intoxication, 
health workers can offer a range of medical and psychosocial services 
to people who use drugs and attend service sites.
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1.4.1 Medical care: referral services
As outlined above, people who use drugs have a range of medical 
problems, and primary health care can be organised and provided at 
the service site. Such sites can link drug users to a range of other social, 
welfare and medical services. People who want to be abstinent can 
be referred to abstinence-oriented drug treatment and rehabilitation 
centres. Appropriate referrals can be made to voluntary counselling 
and testing centres, antiretroviral therapy clinics, tuberculosis clinics or 
hospitals, and other tertiary medical and surgical services. Some people 
enter closed settings where withdrawal management can be provided. 
For details related to management in closed settings, please refer to 
Training manual for clinical guidelines for withdrawal management and 
treatment of drug dependence in closed settings, published by the 
WHO Regional Office for the Western Pacific in 2009.
1.4.2 Mental health: referral services
Many people who use alcohol and drugs have mental health problems, 
with half of those dependent on drugs estimated to have mental health 
problems of varying severity. It is necessary to screen regularly for 
mental health problems and be able to provide essential mental health 
interventions for people who use drugs and attend the service site.
Whereas serious psychiatric disorders can be referred to specialist 
services, identifying and assessing common mental disorders can be 
efficiently done by health workers at the service site. The following 
section deals with the diagnosis and management of common mental 
health problems among people who use drugs.
Detailed information related to primary health care for injecting drug 
users can be obtained from the following:
•	 WHO Myanmar Country Office 2006, Guidelines for primary health 
care services for injecting drug users, Yangon.
•	 WHO Regional Office for South-East Asia 2009, Management of 
common health problems of drug users, New Delhi.
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Section 2 
Assessing and managing common mental 
health problems among people who use drugs 
and attend HAARP service sites (for use by 
trained mental health professionals)
2.1 Psychiatric assessment
A health worker’s encounter with people who use drugs is an opportunity to 
understand their difficulties and begin to establish a therapeutic relationship.
As people who use drugs often have co-occurring mental health 
problems, it is important to detect them at an early stage so that they 
can be managed effectively. Service sites provide opportunities for 
health workers to establish good therapeutic relationships with people 
who use drugs, and this can facilitate comprehensive psychiatric 
assessment. Psychiatric histories and mental status examinations are 
the two essential components of assessment for psychiatric disorders.
2.1.1 Psychiatric history
The psychiatric history allows one to understand the patient, as it is 
a record of the patient’s life. Apart from obtaining information from 
the patient, it may be necessary to gather information from significant 
family members such as parents, the spouse or siblings. The information 
is gathered through interviews. Setting the stage for a meaningful 
interview requires patients to feel comfortable and assured of the 
privacy and confidentiality of the information provided to the health 
worker. Maintaining eye contact during the interview facilitates good 
communication between the health worker and the patient. Sufficient 
time needs to be allotted to listen to the life story of the individual. 
Before beginning the interview, the health worker needs to explain the 
purpose of the interview and outline its objectives, which are to find out 
what kind of problems the person has and how the health worker can 
help. Knowing about the client’s expectations, needs and preferences 
from the service is important.
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A structure for the psychiatric history is provided below.
Box. Outline of a psychiatric history
Identification data
Age
Gender
Occupation
Marital (or relationship) status
Living arrangements
Employment status
Presenting complaints
Chief complaints and their duration
History of present illness
Onset of illness
Precipitating factors
Course of illness
Current status
Past psychiatric history
Family psychiatric history
Medical history
Personal history
Childhood, education, employment, relationships, children
Substance use history
Screening for alcohol and drug use (see appendix)
Detailed history of substance use (see section 1.1.3)
Premorbid personality
Premorbid characteristics and personality traits
2.1.2 Mental status examination
The mental status examination describes the observations and 
impressions of the patient obtained during the interview by the examiner 
(the health worker interviewing the patient). It is the description of the 
patient’s appearance, speech, thoughts, emotions and actions during 
the interview. The examiner records careful observations in a structured 
format. Whereas psychiatric history does not change, mental status can 
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change from day to day or even within hours. The format of a mental 
status examination is outlined below.
Box: Outline of a mental status examination
Appearance and behaviour
Appearance, psychomotor behaviour, eye contact and rapport
Speech
Rate, rhythm and volume and whether relevant and coherent or not 
(comment)
Mood and affect
The client’s subjective description of his or her mood
The examiner’s objective observation (anxious, sad, euphoric, irritable, 
incongruous or blunted)
Intensity, diurnal variation of mood
Thoughts
Content
Persecutory, grandiose, hypochondriacal, guilty or jealous
Obsession, overvalued ideas or delusions
Suicidal thoughts
Perception
Illusions
Hallucinations
Content (auditory, visual, tactile or olfactory)
Cognitive state
Alertness
Attention and concentration
Orientation
Memory
Calculations
Abstract reasoning
Insight
Judgement
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2.2 Assessing and managing common mental health 
symptoms
2.2.1 Anxiety
Anxiety that is pathological occurs in two forms: anxiety that is more or less persistent 
(generalised anxiety) and anxiety that occurs in discrete attacks (acute anxiety attacks).
2.2.1.1 Clinical features
Persistent anxiety is manifested as fear of unknown origin, a feeling of 
tremulousness, palpitation, racing of the heart and profuse sweating 
(evident on a handshake with an anxious person). Depending on the 
cause, the duration of anxiety may vary. This condition is also known as 
generalised anxiety disorder.
In acute anxiety, the attacks typically arise suddenly and have a span of 
some minutes, with symptoms rapidly reaching a crescendo. In addition 
to extreme anxiety, the patient has tremors, palpitations, excessive 
sweating, difficulty in breathing, light-headedness, nausea and altered 
sensations. The duration is generally brief. Acute anxiety attacks may 
be seen in panic disorder, post-traumatic stress disorder and phobias.
The common causes of persistent anxiety among people who use drugs 
are alcohol withdrawal, benzodiazepine withdrawal and generalised 
anxiety disorder. The frequent causes of acute anxiety attacks are 
panic disorder, substance-induced panic episodes, hypoglycaemia 
and hyperventilation.
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Table 18 Causes of anxiety
Substance withdrawal
Alcohol
Sedative/hypnotic– benzodiazepines
Nicotine
Toxic
Caffeine
Theophylline
Sympathomimetic drugs
Cannabis
Hallucinogens
Cocaine
Others 
Temporal lobe epilepsy
Angina
Pulmonary embolus
Parkinson disease
Traumatic brain injury
Chronic obstructive pulmonary disease
Hyperthyroidism
Metabolic
Hypoglycaemia
Hyperventilation
2.2.1.2 Clinical assessment
Take a psychiatric history and conduct a mental state examination and 
appropriate physical examination.
Key points
•	 Is there a temporal relationship between substance use and anxiety?
•	 Is there a physical illness that explains the anxiety?
•	 When did the anxiety appear first? During adolescence?
•	 Is there any evidence of a psychiatric disorder such as generalised 
anxiety disorder or panic disorder?
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2.2.1.3 Risk management
Distress and suicidality that are secondary to anxiety can be acutely 
alleviated with sedation administered orally (diazepam 5–10 mg or 
lorazepam 1–2 mg) or by IM (Lorazepam 1–2 mg).
Manage the underlying disorder.
Generalised anxiety disorder
Diagnosis
Table 19 Diagnostic features of generalised anxiety disorder
Excessive worry and apprehension
Difficulty in controlling worry
Associated symptoms
Restlessness or nervousness
Fatigue
Difficulty in concentrating
Irritability
Tension
Trembling
Muscular tension
Sweating
Light-headedness
Palpitations
Dizziness
Discomfort in the abdomen
Sleep disturbance
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Treatment
•	 Relaxation techniques (e.g. Jacobson muscle relaxation technique).
•	 Supportive psychotherapy (reassurance, explanation, expert advice, 
suggestions, guidance, ventilation, support and facilitating emotional 
support from key people).
•	 Pharmacotherapy.
Selective serotonin reuptake inhibitors (SSRIs) are effective in controlling 
symptoms and should be used as a first line of therapy.
Other treatments are mirtazapine, venlafaxine, beta blockers (useful for 
somatic symptoms, particularly tachycardia), imipramine, clomipramine, 
etc. (see section 2.3.2).
Benzodiazepines are prescribed only for a short period of time. It is better 
to avoid benzodiazepines for treating generalised anxiety disorder, as 
they should not be used in response to the minor stresses of everyday life. 
Alcohol and CNS depressants potentiate the effects of benzodiazepines. 
Driving should be avoided.
Patient education is critical to effectively managing generalised anxiety disorder. 
Panic disorder
Diagnosis
Table 20 Diagnostic features of panic disorder
Discrete and intense period of anxiety, apprehension and distress
Associated symptoms
Palpitations
Sweating
Trembling
Dizziness or light-headedness
Depersonalisation or derealisation
Fear of becoming insane
Fear of dying
Dyspnoea or choking sensation
Chest pain or discomfort
Paraesthesia or altered sensations
Gastrointestinal upset
Chills or hot flushes
Urgent desire to flee (agoraphobia may occur with or without panic and vice versa)
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Treatment
Antidepressants: SSRIs are the first-line drug treatment.
Other drugs: These are mirtazapine, venlafaxine, sodium valproate, 
imipramine and clomipramine (see section 2.3.2).
Benzodiazepines: The target dose of clonazepam for panic disorder 
is 1 mg per day, though some people benefit from doses up to 4 mg 
per day. When a person stops taking clonazepam, the drug should 
be gradually discontinued. Decrease the twice-daily dose by 0.125 
mg every 3 days. To prevent misuse, the prescription should be short 
term and patients provided with counselling. If necessary, medication 
should be dispensed daily.
Table 21 Comparison of generalised anxiety disorder and panic disorder
Generalised anxiety 
disorder Panic disorder
Clinical presentation Irrational worries
Motor tension
Hypervigilance
Somatic symptoms
Sudden, unpredictable 
episodes of severe anxiety
Shortness of breath
Fear of suffocation and 
dying 
Urgent desire to flee
Emergency 
management
Benzodiazepines for 
short-term use only, up to 
2–4 weeks
Benzodiazepines for short-
term use only
First-line drug 
treatment 
SSRIs
Venlafaxine
SSRIs
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2.2.2 Agitation and aggression
Agitation is an extremely common symptom. Agitated people are tense and 
restless, and some may become assaultive and violent. A variety of conditions 
can cause agitation and aggression.
2.2.2.1 Common causes of agitation
•	 Stimulant intoxication
•	 Withdrawal from substances
•	 Psychosis
•	 Delirium
•	 Mania
2.2.2.2 Clinical features of an agitated person
•	 Tense and restless
•	 Pacing up and down
•	 Shouting and cursing
•	 Violent
•	 Assaultive
2.2.2.3 Short-term risk management
Risks to self
•	 From deliberate self-harm
•	 From self-neglect
•	 From being vulnerable to others
Risks to others
•	 By aggression
•	 By neglect of others
Assessment consists of a mental status examination and collecting the 
information necessary to establish a diagnosis.
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Table 22 Short-term management of aggressive behaviour
Step Intervention
1. De-escalation
Try to reduce arousal.
Remove the person to a place with little stimulation.
Shift the person to a place where she or he feels more 
comfortable.
2. Offer oral treatment
An oral antipsychotic is an option for patients who are not 
already taking a antipsychotic: haloperidol 5 mg, olanzapine 
10 mg, risperidone 1–2 mg or quetiapine 100–200 mg.
If the patient is prescribed a regular antipsychotic, use 
lorazepam 1–2 mg or promethazine 25–50 mg. Repeat after 
45–60 minutes.
Go to step 3 if step 2 fails (or sooner if the patient is placing 
self or others at significant risk).
3. From this step, 
consider consulting 
a specialist.
Consider IM treatment
Inject lorazepam 1–2 millilitre
Inject promethazine 50 mg, which is a useful option for  
benzodiazepine-tolerant patients
Inject haloperidol 5–10 mg.
Repeat after 30–60 minutes if the effect is insufficient.
Injecting lorazepam alone or in combination with haloperidol is useful 
for containing aggression in psychotic disorders and substance-
induced intoxication such as ATS toxicity and agitation related to 
acute alcohol withdrawal. Some patients may require hospitalisation 
to manage the condition. For the treatment of stimulant intoxication 
and alcohol withdrawal, see sections 1.3.2 and 1.2.3. The treatment of 
psychosis and mania is dealt with in section 2.2.5 and the management 
of delirium in section 2.2.3.
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2.2.3 Delirium
Given high mortality among patients with delirium, identifying delirium and 
referring patients to hospital is important. The tasks are to assess the underlying 
cause of delirium, provide support and offer pharmacological treatment for 
symptomatic relief.
2.2.3.1 Causes of delirium
Substance use
Withdrawal
Alcohol withdrawal (delirium tremens)
Benzodiazepine withdrawal
Barbiturate withdrawal
Intoxication
Amphetamine
Cocaine
Cannabis
Inhalants
Phencyclidine
Medications that induce delirium
Analgesics (propoxyphene)
Anticholinergics (trihexyphenidyl)
Anticonvulsants (phenytoin)
Antidiabetics (insulin and oral antidiabetic drugs)
Antihypertensives (clonidine)
Corticosteroids (prednisone)
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Cardiovascular drugs (digoxin)
Gastrointestinal agents (cimetidine)
Psychotropics (antidepressants, anxiolytics)
Other disorders and illnesses that can cause delirium
Thiamine deficiency
Infection
Hypoglycaemia
Fluid and electrolyte imbalance
Head trauma
Seizures
Hepatic failure
Hypoxia
Anaemia
Heart attack
Congestive cardiac failure
2.2.3.2 Clinical features of delirium
•	 Confusion (clouding of the senses) and disorientation are the 
cardinal signs of delirium.
•	 ‘Sundowning’ is common, wherein the confusion worsens with the 
coming of darkness.
•	 Other signs may or may not be there, such as disturbance of 
attention, thinking, memory, psychomotor behaviour, emotion, 
sleep–wake cycle, etc.
•	 One may also notice perceptual disturbances (hallucinations) or, at 
times, fragmentary delusions, agitation or disquietude.
•	 The onset of delirium is often acute or subacute.
2.2.3.3 Treatment of delirium
1. Identify the underlying condition.
2. Initiate interventions for acute conditions.
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3. Monitor and ensure safety.
4. Educate patients and families about the nature of the problem.
Table 23 Non-pharmacological treatment of delirium
Environmental measures
Provide consistent, supportive nursing care.
Minimise the number of attendants.
Place the patient in a well-lighted room with a window.
Have a familiar person by the side of the patient.
Supportive measures
Provide fluid and electrolyte balance.
Ensure nutrition and vitamin intake.
Moderate sensory input.
Encourage ambulation.
Impose physical restraint when necessary.
Pharmacological treatment
Regarding withdrawal from substances such as alcohol and 
benzodiazepines, see sections 1.2.3 and 1.2.4. Withdraw the offending 
agent or treat the underlying condition.
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Table 24 Pharmacological treatment of symptoms in delirium
Symptom Pharmacological treatment
Sleep disturbance Lorazepam oral or IM 0.25–1.00 mg every 2–4 hours 
as needed, up to 3.00 mg in 24 hours
Diazepam oral starting dose of 5–10 mg
Disruptive behaviour Haloperidol oral 0.5–1.0 mg twice daily with 
additional doses every 4 hours as needed; IM 0.5–1.0 
mg, observe for 30–60 minutes and repeat every 4 
hours as necessary
Watch for extrapyramidal symptoms such as rigidity, 
tremors or dystonia.
Second-generation antipsychotics are indicated for 
oral use: olanzapine 2.5–5.0 mg once daily, usual 
maximum of 20.0 mg/day.
Risperidone 0.5 mg twice daily with additional doses 
every 4 hours as needed, usual maximum of 4.0 mg/
day
Quetiapine 12.5–25.0 mg twice daily, which may be 
increased every 1–2 days to 100.0 mg daily if it is well 
tolerated
2.2.4 Depression
Depression is a common mental health problem that is more prevalent in 
women than in men. Its sequelae include suicide; dependence on sedative–
hypnotics, alcohol and drugs; disability; and elevated rates of medical morbidity 
and mortality. The impact of recognition and effective treatment of depression 
is considerable.
Depression is a common mental health problem, affecting 20% 
or more of people at some point during their lifetime. It is more 
prevalent in people who use drugs and the most common co-morbid 
psychiatric disorder.
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2.2.4.1 Causes of depression
Primary disorders
Major depressive disorder
Bipolar depression
Premenstrual depression
Postpartum depression
Chronic alcoholism
Substance withdrawal
Stimulants
Anabolic steroids
Toxic depression (medication-induced)
Prednisone
Alpha interferon
Propranolol
Nifedipine
Ranitidine
Metabolic
Vitamin deficiency including Pellagra
Endocrine
Hypothyroidism
Cushing syndrome
Others
Multi-infarct dementia
Traumatic brain injury
Stroke
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2.2.4.2 Clinical features
Table 25 Clinical features of depression
Depressed or sad mood, crying
Irritability
Low self-esteem; guilt or pessimism
Suicidal ideation
Difficulty in concentrating or forgetfulness
Lack of interest in pleasurable activities (anhedonia)
Lack of energy (anergia)
Sleep disturbance
Appetite disturbance (anorexia)
Agitation or retardation
2.2.4.3 Risk assessment and management
The most important aspect of depression is suicidality. Assessing 
the risk of suicide is important in all patients presenting depressive 
symptoms. People who use drugs have a higher risk for suicidality, 
particularly those with co-morbid depressive disorders.
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Table 26 Assessment of suicide risk
1. What is the current degree of suicidal ideation?
a. Actively suicidal (any plans?)
b. Ambivalent about suicide
c. Passively suicidal
d. No ideation
2. Previous suicide attempts
a. Number of previous attempts
b. Those that required medical intervention
3. What is the psychiatric status?
a. Is the person psychotic?
b. Is there drug or alcohol dependence?
4. What is the level of social support?
5. What are the other risk factors (older, male, living alone, unemployed)?
It is important to arrange appropriate treatment, depending on the 
underlying condition. Depressive patients who are suicidal may be 
helped by hospitalisation and by specialist care with electroconvulsive 
therapy and antidepressants. It is extremely important to be vigilant, 
and family members have to be educated and counselled about the 
suicidal behaviour of the patient.
2.2.4.4 Major depressive disorder
Major depressive disorder is the one of the most common causes of 
depressive syndrome and is a prevalent co-morbid psychiatric disorder 
among people who use drugs.
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Diagnostic features
•	 Any five of the following:
Depressed mood
Lack of pleasure or loss of interest in usual activities such as 
work and household duties
Appetite disturbance or weight loss or gain
Sleep disturbance
Motor agitation or retardation
Fatigue or loss of energy
Guilt or feelings of worthlessness
Concentration difficulties or indecisiveness
Suicidal ideation or thoughts of death.
•	 Distress or impairment in social, occupational or other areas of 
functioning.
•	 Not attributable to general medical condition or caused by 
substance use, grief or bereavement.
Pharmacotherapy for major depressive disorder
For moderate-to-severe depressive disorder, antidepressants are the 
first choice. For those who experience additional psychotic symptoms, 
the addition of second-generation antipsychotics may be considered.
Antidepressants (see section 2.3.2):
Tricyclic antidepressants: imipramine, amitriptyline, dothiepin, trazodone
Selective SSRIs: fluoxetine, sertraline, citalopram, escitalopram, 
paroxetine
Serotonin norepinephrine reuptake inhibitors: venlafaxine
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2.2.5 Psychosis
Psychosis is a disruptive mental state in which an individual has difficulty 
distinguishing external reality from his or her own internal experiences and 
perceptions. As psychosis can be caused by several disorders, it is important 
to diagnose the underlying condition to enable evidence-based treatment. 
Antipsychotics are beneficial in managing psychotic disorders.
2.2.5.1 Causes of psychosis
•	 Psychosis induced by ATS or other substances
•	 Alcoholic hallucinosis
•	 Acute psychotic disorder
•	 Schizophrenia
•	 Bipolar disorder, mania
•	 Depression
•	 Delusional disorder
•	 Delirium
•	 Dementia
•	 Head injury.
2.2.5.2 Presenting complaints
•	 Hearing voices when no one is around, seeing visions
•	 Strange beliefs or fears
•	 Confusion
•	 Apprehension
•	 Abnormal behaviour.
2.2.5.3 Diagnostic features
Recent onset of the following:
•	 hallucinations (e.g. hearing voices when no one is around, seeing visions).
•	 delusions (firmly held ideas that are often false and not shared by 
others in the patient’s social, cultural or ethnic group, e.g. patient 
believes he or she is being poisoned by neighbours, receiving 
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messages from the television, or being looked at and talked about 
by others in some special way).
•	 strange (disjointed) speech.
•	 agitation.
•	 bizarre behaviour.
•	 extreme and labile emotional states.
•	 These symptoms may be preceded by a period of deteriorating 
social, occupational or academic functioning.
2.2.5.4 Management of psychosis
Psychosis can be effectively managed using antipsychotics (see section 2.3.3).
Antipsychotics that are available as injectable preparations and can be 
used for acute management include haloperidol and chlorpromazine, 
though the latter is no longer recommended.
Table 27 Injected haloperidol dosage for the acute management of 
psychotic behaviour
Degree of agitation Dose (mg)
Mild 0.5–2.0 
Moderate 2.0–10.0
Severe 10.0–40.0
Symptoms that are modified by antipsychotics include the following:
•	 hallucinations and illusions
•	 delusions and suspiciousness
•	 thought disturbances
•	 hyperactivity and agitation
•	 mental confusion
•	 perplexity.
Social withdrawal and negative symptoms generally respond poorly 
to conventional antipsychotic medications such as haloperidol and 
chlorpromazine. Atypical antipsychotics such as risperidone and 
olanzapine are the drugs of choice for managing negative symptoms.
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For managing the side-effects of antipsychotics, see the appendix.
2.2.5.5 Features of the major causes of psychosis
Schizophrenia
Diagnostic features
At least two of the following should be present for at least 6 months 
and not attributable to substance use, general medical disorders or 
mood disorders:
•	 delusions
•	 hallucinations
•	 disjointed speech
•	 grossly disorganised or catatonic behaviour
•	 negative symptoms
•	 social or occupational dysfunction.
Criteria for paranoid schizophrenia (subtype)
Preoccupation with delusions or frequent auditory hallucinations
Bipolar disorder, mania
Diagnostic features
Manic episode
Diagnosis requires a distinct period of mood disturbance lasting more 
than a week and any three of the following symptoms, not attributable 
to substance use or general medical conditions:
•	 inflated self-esteem and grandiosity
•	 decreased need for sleep
•	 more talkative than usual
•	 flights of ideas and racing thoughts
•	 distractibility
•	 increase effort in goal-directed activity
•	 extensive involvement in pleasurable activities.
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Alcoholic hallucinosis
Alcoholic hallucinosis usually occurs during alcohol withdrawal. This 
condition is a hallucinatory or delusional state with clear or relatively 
clear consciousness. Hallucinations tend to be voices with sexual or 
derogatory content, and delusions are paranoid. These states are 
related not only to sudden withdrawal of alcohol but can also occur 
during prolonged, steady drinking. The course of these states sets 
them apart from other alcohol withdrawal states, as the condition lasts 
for months rather than days or weeks. At times, it is a challenge to 
differentiate this from paranoid schizophrenia.
Table 28 Differences between alcoholic hallucinosis and paranoid 
schizophrenia
Feature Alcoholic hallucinosis
Paranoid 
schizophrenia
Age of onset
Type of onset
Duration of illness
Pre-morbid personality
Alcohol dependence
Family history of 
alcoholism
Family history of 
schizophrenia
Hallucinations and 
delusions
Thought processes
Affect
Intellectual function
Orientation
40–50 years
Usually acute
3 months
Varied
Over many years
Likely
No evidence
Auditory but may also be visual 
and tactile
Coherent
Anxious, depressed and 
perplexed but appropriate
Fleeting memory disturbance
At times not oriented to time
Before 40 years
Insidious
Chronic
Shy, aloof, withdrawn
Not usually present
Not usually present
Increased prevalence
Auditory
Incoherent
Inappropriate
Not compromised
Not compromised
For drug-induced psychosis, refer to section 1.3.2.
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2.2.6 Sleep disturbance (insomnia)
Sleep problems are highly prevalent among people who use drugs. Episodes of 
insomnia are extremely distressing and can trigger relapse following a period 
of abstinence.
2.2.6.1 Presenting complaints
•	 Difficulty in falling asleep
•	 Recurrent waking during the night
•	 Early morning awakening
•	 Not feeling fresh after a night’s sleep
•	 Falling asleep at inappropriate times during the day.
Features associated with sleep disturbance are as follows:
•	 reduced quality of life
•	 general ill health, alcohol and drug misuse
•	 poor work performance
•	 difficulties in concentration.
2.2.6.2 Differential diagnosis
Table 29 Differential diagnosis of insomnia
Type of insomnia Causes
Transient insomnia Worries, family disputes
Withdrawal from hypnotic drugs
Brief illness
Short-term insomnia Bereavement
Chronic insomnia Poor sleep hygiene
Drug or alcohol dependence
Depression
Bipolar disorder
Anxiety disorder
Psychotic illnesses
Drug withdrawal and intoxication
Tolerance of benzodiazepines and alcohol
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2.2.6.3 Management of insomnia
Risk management
Sleep disorder must be comprehensively assessed. Assessment 
should include a full sleep history from the patient; examination of the 
mental state; and review of medical, psychiatric and family histories. A 
sleep diary can be valuable. Suicide is often associated with chronic 
sleep problems.
Distinguishing the nature of insomnia and its underlying cause is 
important. The common causes are poor sleep hygiene, depression 
and substance use. Sleep hygiene is most important. Treat the 
underlying disorder with appropriate medications. For patients already 
using psychotropics, one can avoid using hypnotics by choosing or 
changing to a sedative type of psychotropic medication. If a hypnotic 
is required, administer it for only a short period. Hypnotics should not 
be prescribed long term to people who use drugs.
Measures used to improve sleep hygiene
•	 Arise at the same time each day.
•	 Limit time in bed to a normal duration of 6–7 hours daily.
•	 Discontinue the use of drugs that act on the CNS such as caffeine, 
tobacco, alcohol, opioids and stimulants.
•	 Avoid daytime napping.
•	 Exercise in the morning and remain active throughout the day.
•	 Substitute watching television at night with light reading and 
listening to music.
•	 Have a warm bath near bedtime.
•	 Eat on schedule and avoid large meals at night.
•	 Follow an evening relaxation routine.
•	 Ensure comfortable sleeping conditions.
•	 Spend no longer than 20 minutes awake in bed.
•	 Use the bed only for sleep (and sex!).
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Drugs used as hypnotics (dose per day)
•	 Nitrazepam or diazepam  5–10 mg
•	 Zolpidem  5–10 mg
•	 Zopiclone  3.75–7.50 mg
•	 Zaleplon  10 mg
•	 Promethazine 25–50 mg
•	 Melatonin  2 mg
2.2.7 Seizures (fits)
A seizure, or ictus, is paroxysmal in onset, generally brief in duration and 
secondary to an equally paroxysmal electrical discharge within the grey matter 
of the brain. As a variety of conditions can cause seizures, it is important to 
recognise the underlying condition to appropriately treat it.
2.2.7.1 Causes of seizures
•	 Idiopathic generalised seizures
Generalised epilepsy with tonic–clonic seizures
•	 Alcohol, sedative or hypnotic withdrawal
Alcohol
Benzodiazepines
•	 Intoxicants
Cocaine
Phencyclidine
•	 Metabolic
Hypoglycaemia
Hypernatraemia
Uraemia
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•	 Medications
Tricyclic antidepressants
Phenothiazines
Isoniazid
Theophylline
•	 Others
Meningitis, encephalitis
Cerebrovascular disorders
2.2.7.2 Treatment
Treating the underlying condition is important. When this is not 
possible, utilising an antiepileptic drug (AED) is appropriate. Idiopathic 
generalised epilepsy generally responds to treatment with valproic 
acid, which is a reasonable choice for non-focal grand mal seizures. 
Phenytoin is another AED that is widely employed to control grand 
mal seizures. Carbamazepine is used to treat grand mal and partial 
seizures. Phenobarbital is an AED that is cheap and effective and has 
few side-effects. Diazepam is the drug of choice for managing status 
epilepticus. Lorazepam, a long-acting benzodiazepine, is another drug 
used to treat status epilepticus.
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2.3 Psychotropic drugs commonly used to manage mental 
health problems
2.3.1 Antianxiety agents
Table 30 Commonly used antianxiety agents and their side-effects*
Drug** and its 
half-life Dose range
Use and common side-
effects (CSE) Caution
Alprazolam
12–15 hours
0.25–0.50 mg 
3 times daily for 
panic, not to exceed 
3.00 mg/day
Use: panic
CSE: drowsiness, 
dizziness, lethargy, 
confusion, paradoxical 
excitation, nausea, 
vomiting
Risk for dependence; 
withdrawal syndrome on 
sudden discontinuation; 
interaction with alcohol, 
antidepressants, 
antihistamines, opioids and 
other benzodiazepines
Chlordiazepoxide
5–30 hours
Anxiety: 10 mg 
orally 3–4 times daily
Alcohol withdrawal: 
30–90 mg
Use: adjunct to anxiety 
management; alcohol 
withdrawal
CSE: drowsiness, 
dizziness
Contraindicated: narrow-
angle glaucoma, caution in 
hepatic or renal impairment, 
history of substance use
Clonazepam
18–50 hours
Range: 0.5–4.0 mg/
day orally, up to 6.0 
mg/day
Use: panic, seizure 
disorder
CSE: drowsiness, ataxia, 
behavioural changes
Contraindicated: severe liver 
disease 
Diazepam
20–50 hours
Range: 4–40 mg/day
Anxiety: 2–10 mg 
orally 2–4 times daily
Alcohol withdrawal: 
10 mg orally 3–4 
times in first 24 
hours, then 5 mg 
3–4 times daily
Use: adjunct to anxiety 
management; alcohol 
withdrawal
CSE: drowsiness, 
dizziness, lethargy
Monitor for dependence; in 
prolonged therapy, monitor 
liver and renal functions
Lorazepam
10–16 hours
Range: 2–4 mg/day 
in divided doses
Insomnia: 2–4 mg 
orally at bedtime
Use: anxiety, alcohol 
withdrawal, insomnia
CSE: drowsiness, 
dizziness, lethargy
Rapid intravenous: 
apnoea, cardiac arrest
Contraindicated: CNS 
depression, pregnancy, 
lactation, glaucoma
Caution: hepatic, renal or 
pulmonary impairment; 
monitor for dependence
* For warnings related to benzodiazepines, see appendix.
** Regarding the use of benzodiazepines in the acute management of agitation and aggression, see section 2.2.1.
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2.3.2 Antidepressants
Table 31 Commonly used antidepressants and their side-effects*
Drug and its 
half-life Dose range
Use and common side-
effects (CSE) Caution
Amitriptyline
9–25 hours
25–200 mg/day; dosage 
75 mg/day orally in 
divided doses, up to 
200 mg/day; increase by 
25–50 mg
Use: depression
CSE: blurred vision, dry 
eyes, dry mouth, sedation, 
hypotension, constipation, 
arrhythmia 
Contraindicated: 
cardiovascular disease
High doses have more 
side-effects.
Monitor electrocardiogram 
(ECG) 
Dothiepin
8–25 hours
25–225 mg/day orally; 
25 mg orally 3 times 
daily, up to 225 mg/day 
Use: depression, anxiety
CSE: blurred vision, dry 
eyes, dry mouth, sedation, 
hypotension, constipation
ECG monitoring of 
patients with history of 
cardiovascular disease
Monitor blood pressure 
and pulse
Imipramine
19 hours
10–200 mg/day; 25–50 
mg orally 3–4 times 
daily, up to 300 mg/day 
for hospitalised patients
Use: depression, panic
CSE: blurred vision, dry 
eyes, dry mouth, sedation, 
hypotension, constipation, 
arrhythmia
ECG monitoring of 
patients with history of 
cardiovascular disease
Monitor blood pressure 
and pulse
Avoid use with clonidine
SSRIs
Fluoxetine
4–6 days 
20 mg orally  
Depression: 
start 20 mg/day orally
Use: depression, obsessive–
compulsive disorder (OCD), 
bulimia nervosa
CSE: anxiety, drowsiness, 
headache, insomnia, 
nervousness, diarrhoea, 
sexual dysfunction, 
itchiness, increased 
sweating, tremors
Caution: Hepatic or renal 
impairment, pregnancy, 
seizures, history of mania,
hyponatraemia
SSRIs
Sertraline
26 hours
50–200 mg/day 
Depression: 
start 50 mg/day orally; 
may increase slowly to 
200 mg/day
Panic disorder: start 25 
mg/day orally, up to 50 
mg/day
Use: depression, panic 
disorder, OCD, post-
traumatic stress disorder, 
social anxiety disorder
CSE: drowsiness, 
dizziness, headache, 
fatigue, insomnia, 
nausea, diarrhoea, sexual 
dysfunction, dry mouth, 
increased sweating, tremors
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania
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Drug and its 
half-life Dose range
Use and common side-
effects (CSE) Caution
SSRIs
Citalopram
33 hours
20–60 mg/day (use 
lower dose)
Depression: start with 
20 mg
Panic disorder: start with 
10 mg
CSE: drowsiness, 
dizziness, headache, 
fatigue, insomnia, 
nausea, diarrhoea, sexual 
dysfunction, dry mouth, 
increased sweating, tremors
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania
SSRIs
Escitalopram
30 hours
10–20 mg/day
Depression: start with 10 
mg/day
Panic disorder: start with 
5 mg/day for 1 week, 
increasing to 20 mg/day
Use : depression, panic, 
social anxiety, generalised 
anxiety disorder, OCD
CSE: drowsiness, 
dizziness, headache, 
fatigue, insomnia, 
nausea, diarrhoea, sexual 
dysfunction, dry mouth, 
increased sweating, tremors
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania
SSRIs
Paroxetine
24 hours
20–50 mg/day (use low 
dose)
Use and CSE: drowsiness, 
dizziness, headache, 
fatigue, insomnia, 
nausea, diarrhoea, sexual 
dysfunction, dry mouth, 
increased sweating, tremors
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania 
Mirtazapine
20–40 hours
15–45 mg/day Use: depression
CSE: increased appetite, 
weight gain, drowsiness, 
oedema, dizziness, 
headache, blood dyscrasia
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania and blood 
disorders
Trazodone
5–13 hours
150–300 mg/day Use: depression, 
generalised anxiety 
disorder
CSE: sedation, dizziness, 
headache, nausea, 
vomiting, tremors, postural 
hypotension, tachycardia, 
priapism
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania and avoid use 
with sedatives, alcohol, 
other antidepressants, 
digoxin or phenytoin 
Venlafaxine
5 hours
75–375 mg/day Use: depression, 
generalised anxiety 
disorder
CSE: sedation, dizziness, 
headache, nausea, 
vomiting, tremors, postural 
hypotension, tachycardia, 
priapism
Caution: Hepatic or renal 
impairment, pregnancy, 
lactation, seizures, history 
of mania and avoid in 
arrhythmia
* Antidepressants are also used often as antianxiety drugs; SSRIs are the first line of treatment for 
depression and anxiety disorders.
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2.3.3 Antipsychotics
Table 32 Commonly used antipsychotics and their side-effects
Drug and its 
half-life Dose range
Use and common side-
effects (CSE) Caution
Chlorpromazine
16–30 hours
25–1000 mg/day orally
Psychosis: 10–25 mg 
orally 2–4 times/day; may 
increase to 1000 mg/day
IM: start 25–50 mg 
IM, up to 400 mg/day 
for acute psychotic 
conditions
Use: psychoses, bipolar 
disorders, agitation
CSE: hypotension, dry 
eyes, sedation, blurred 
vision, constipation, dry 
mouth, photosensitivity,
neuroleptic malignant 
syndrome (NMS) 
Contraindicated: 
glaucoma, bone marrow 
depression, severe liver 
disease
Monitor blood pressure, 
pulse and respiration
Watch for extrapyramidal 
symptoms (akathisia), 
tardive dyskinesia, NMS 
Haloperidol
12–36 hours
1–30 mg/day;
0.5–5.0 mg orally 2–3 
times daily up to 30.0 
mg/day
IM: 5.0–10.0 mg stat
Use: psychoses, drug-
induced psychoses, 
bipolar disorder, 
aggressive states
CSE: extrapyramidal 
symptoms, blurred vision, 
dry eyes, dry mouth, 
constipation
NMS, seizures
Monitor blood pressure 
and pulse, respiration, 
extrapyramidal 
symptoms (akathisia), 
tardive dyskinesia, NMS, 
corrected QT interval 
prolongation on ECG
Trifluoperazine
13 hours
10–30 mg/day, starting 
with 5 mg/day; can be 
given into two divided 
doses
Use: psychoses
CSE: extrapyramidal 
symptoms, blurred vision, 
dry eyes, dry mouth, 
constipation, NMS
Contraindicated: 
bone morrow problems, 
hepatic impairment, 
blood disorders, allergy to 
chlorpromazine
Risperidone
20–24 hours
1–16 mg/day
Dosing may be once 
daily
Start 1 mg orally twice 
daily and slowly increase
Use: psychoses, bipolar 
disorder, aggression, 
irritability associated with 
autism
CSE: extrapyramidal 
symptoms (akathisia), 
dizziness, aggression, 
insomnia, sedation, dry 
mouth, cough, itching, 
constipation, weight gain, 
NMS
Caution: Renal or hepatic 
impairment
Increased dose 
>6 mg heightens 
risk of developing 
extrapyramidal symptoms
Monitor blood pressure 
and pulse
Olanzapine
21–54 hours
5–20 mg/day
Start 5–10 mg/day
Use: psychoses, bipolar 
disorder
CSE: agitation, dizziness, 
sedation, constipation, 
weight gain
Monitor for treatment-
emergent diabetes,
blood sugar, basal 
metabolic rate, lipid 
profile, NMS, seizure
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Drug and its 
half-life Dose range
Use and common side-
effects (CSE) Caution
Quetiapine
4–10 hours
150–800 mg/day
Start with 25 twice on 
first day, 50 mg twice 
on second day, then 
increase by 50 mg/day
Use: psychoses, bipolar 
disorder
CSE: rash, problems with 
balances, mood changes, 
weight gain, constipation 
dizziness or drowsiness
Monitor for treatment-
emergent diabetes,
blood sugar, basal 
metabolic rate, lipid 
profile, NMS, seizure
Aripiprazole
75–146 hours
10–30 mg/day Use: psychoses, bipolar 
disorder
CSE: as above, insomnia 
(but fewer metabolic side-
effects than risperidone, 
olanzapine, quetiapine) 
Monitor for treatment-
emergent diabetes,
blood sugar, basal 
metabolic rate, lipid 
profile, NMS, seizure
2.3.4 Antiepileptic drugs
Table 33 Commonly used antiepileptic drugs (AEDs) and their side-effects*
AED Usual daily dosage Common side-effects
Phenytoin 300–600 mg/day in 
divided doses
Sluggishness, ataxia, nystagmus, confusion, slurred 
speech, dizziness, insomnia, nervousness, fatigue, nausea, 
vomiting, gingival hyperplasia, photophobia, skin rashes, 
megaloblastic anaemia
Carbamazepine 800–1200 mg/day in 
divided doses
Drowsiness, dizziness, fatigue, headache, unsteadiness, 
nausea, diplopia, skin rashes. Stevens–Johnson syndrome 
(requires discontinuation), agranulocytosis, aplastic 
anaemia, thrombocytopenia
Valproate 750–3000 mg/day in 
divided doses
Few serious side-effects; weight gain
Monitor for hepatotoxicity, pancreatitis
A teratogenic drug, it can cause neural tube defects
Phenobarbitol 60–100 mg/day in 
divided doses
Few side-effects; CNS depression, excitability in children
Contraindicated: history of porphyria
*AEDs require careful titration.
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2.3.5 Other psychotropic drugs
Table 34 Other psychotropic drugs and their side-effects
Drug Dose range
Use and common side-
effects (CSE) Caution
Trihexyphenidyl 5–10 mg/day, up to 15 
mg/day
Start 1–2 mg/day 
orally and increase by 
2 mg every 3–5 days
Use: drug-induced 
Parkinsonism
CSE: dizziness, nervousness, 
drowsiness, orthostatic 
hypotension, dry mouth, 
mydriasis, blurred vision, 
constipation, dry mouth, 
tachycardia, urinary 
hesitancy
Contraindicated: 
glaucoma, thyrotoxicosis, 
acute haemorrhage, 
tardive dyskinesia
Additive effects with 
anticholinergic drugs and 
CNS depressants
Procyclidine 5–30 mg/day orally in 
2–4 divided doses
IM: 5–10 mg stat dose
Use: extrapyramidal 
symptoms, acute dystonia 
As above
Propranolol 40–120 mg/day orally Use: essential tremors, 
anxiety, akathisia
CSE: Fatigue, low mood, 
weakness, impotence, 
arrhythmia, bradycardia, 
pulmonary oedema
Contraindicated: heart 
block, bradycardia
Monitor blood pressure 
and pulse
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Appendix
1. Short Opioid Withdrawal Scale*
For each of the following symptoms, assign a score of 0 if not present, 1 if mild, 
2 if moderate and 3 if severe:
•	 Feeling sick
•	 Stomach cramps
•	 Muscle spasms or twitching
•	 Feeling cold
•	 Pounding heart
•	 Muscular tension
•	 Aches and pains
•	 Yawning
•	 Running watery eyes
•	 Difficulty in sleeping.
Add scores for the total score, and compare it with the table below to guide 
the management of withdrawal.
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Table A.1 Short Opioid Withdrawal Scale management by score
Score Suggested withdrawal management
0–10 Mild withdrawal; symptomatic medication only
10–20 Moderate withdrawal; symptomatic or opioid medication
20–30 Severe withdrawal; opioid medication
*Source: M Gossop, ‘The development of a Short Opiate Withdrawal Scale (SOWS)’, Addictive Behaviors, 
vol 15(5),1990, pp. 487–90.
2. Revised Clinical Institute Withdrawal Assessment for 
Alcohol (CIWA-Ar) scale
Patient …………………………………… Date …………….… Time …………… Pulse or 
heart rate (taken for 1 min) …………………… Blood pressure ……………………
NAUSEA AND VOMITING – ‘Do you 
feel sick to your stomach? Have you 
vomited?’
0 – No nausea and no vomiting
1 – Mild nausea with no vomiting
2
3
4 – Intermittent nausea with dry heaves
5
6
7 – Constant nausea, frequent dry 
heaves and vomiting
VISUAL DISTURBANCES – ‘Does the light 
appear to be too bright? Is its colour 
different? Does it hurt your eyes? Are you 
seeing anything that is disturbing to you? 
Are you seeing things you know are not 
there?’
0 – Not present
1 – Very mild sensitivity
2 – Mild sensitivity
3 – Moderate sensitivity
4 – Moderately severe hallucinations
5 – Severe hallucinations
6 – Extremely severe hallucinations
7 – Continuous hallucinations
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TREMORS – Arms extended and 
fingers spread apart
0 – No tremors
1 – Not visible, but can be felt 
fingertip-to-fingertip
2
3
4 – Moderate, with patient’s arms 
extended
5
6
7 – Severe, even with arms extended
TACTILE DISTURBANCES – ‘Have you 
any itching, pins and needles, burning, 
numbness? Do you feel bugs crawling on or 
under your skin?’
0 – None
1 – Very mild itching, pins and needles, 
burning, or numbness
2 – Mild itching, pins and needles, burning, 
or numbness
3 – Moderate itching, pins and needles, 
burning, or numbness
4 – Moderately severe hallucinations
5 – Severe hallucinations
6 – Extremely severe hallucinations
7 – Continuous hallucinations
PAROXYSMAL SWEATS
0 – No sweat visible
1 – Barely perceptible sweating; palms 
moist
2
3
4 – Beads of sweat on forehead
5
6
7 – Drenching sweats
AUDITORY DISTURBANCES – ‘Are you 
more aware of sounds? Are they harsh? Do 
they frighten you? Are you hearing anything 
that is disturbing? Are you hearing things 
you know aren’t there?’
0 – Not present
1 – Very mild harshness or ability to frighten
2 – Mild harshness or ability to frighten
3 – Moderate harshness or ability to frighten
4 – Moderately severe hallucinations
5 – Severe hallucinations
6 – Extremely severe hallucinations
7 – Continuous hallucinations
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ANXIETY – ‘Do you feel nervous?’
0 – No anxiety, at ease
1 – Mildly anxious
2
3
4 – Moderately anxious, or guarded, so 
anxiety is inferred
5
6
7 – Equivalent to acute panic states as 
seen in severe delirium or acute 
schizophrenic reactions
HEADACHE, FULLNESS IN THE HEAD – 
‘Does your head feel different? Does it 
feel like there is a band around it?’ (Do 
not rate for dizziness or light-headedness; 
otherwise, rate severity)
0 – Not present
1 – Very mild
2 – Mild
3 – Moderate
4 – Moderately severe
5 – Severe
6 – Very severe
7 – Extremely severe
AGITATION
0 – Normal activity
1 – Somewhat more than normal activity
2
3
4 – Moderately fidgety and restless
5
6
7 – Paces back and forth during most 
of the interview or constantly 
thrashes about
ORIENTATION AND CLOUDING OF 
SENSORIUM – ‘What day is this? Where 
are you? Who am I?’
0 – Oriented and can do serial additions
1 – Cannot do serial additions or is 
uncertain about date
2 – Disoriented for date by no more than 2 
calendar days
3 – Disoriented for date by more than 2 
calendar days
4 – Disoriented for place and/or person
 
Total CIWA-Ar Score .............................. Rater’s name .................................................
Source: http://adai.washington.edu/instruments/pdf/
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3. Screening for alcohol and drug use
Screening for alcohol use: CAGE questionnaire
Please check the one response to each item that best describes how you have 
felt and behaved over your whole life.
1. Have you ever felt you should cut down on your drinking?
Yes
No
2. Have people annoyed you by criticising your drinking?
Yes
No
3. Have you ever felt bad or guilty about your drinking?
Yes
No
4. Have you ever had a drink first thing in the morning to steady your nerves or 
get rid of a hangover (eye-opener)?
Yes
No
Source: JA Ewing, ‘Detecting alcoholism: The CAGE questionnaire’, Journal of the American 
Medical Association , vol 252, 1984, pp.1905–7.
Screening for other drug use
Screen for other drugs: ATS, opioids, cannabis, benzodiazepines and other 
drugs of misuse.
Cannabis
Cannabis use may be frequent for many people using drugs. It is important to 
recognise the impact of cannabis on the person’s symptoms and quality of life.
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Acute effects
•	 Anxiety and panic, especially in naïve users.
•	 Impaired attention, memory and psychomotor performance while 
intoxicated.
•	 Possibly an increased risk of accident if a person drives a motor vehicle 
while intoxicated with cannabis, especially if cannabis is used with alcohol 
and other drugs.
•	 Increased risk of psychotic symptoms among those who are vulnerable 
because of personal or family history of psychosis.
Chronic effects
Cannabis dependence syndrome is characterised by an inability to abstain 
from or control cannabis use.
•	 Subtle impairments of attention and memory can persist for longer 
periods.
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4. Side-effects of antipsychotics and their 
management
The common side-effects are extrapyramidal side-effects, which should be 
recognised and managed.
Table A.2 Side-effects of antipsychotics and their management
Extrapyramidal 
side-effects Management
Dystonia Appears early in treatment
Includes oculogyric crisis, tongue protrusion, torticollis, and 
laryngeal–pharyngeal constriction
Common in young males
Give antihistaminic or anticholinergic drug immediately
IM route preferable
Reassure the patient
Akathisia Chief cause of noncompliance with treatment
Reassure the patient
Reduce the current dose
Switch to a different antipsychotic drug
Start an antiparkinson drug
Benzodiazepines or propranolol may help
Akinesia Absence of movement
More commonly slow movement (bradykinesia)
Symptoms include fatigue, hypotonia, painful muscles and anergy.
Most anticholinergics are helpful
Drug-induced 
Parkinsonism 
(extrapyramidal 
symptoms)
Assess for tremors, rigidity and bradykinesia
Give anti-Parkinson drugs
Tardive dyskinesia Often seen after withdrawal of antipsychotics
Anticholinergic drugs worsen tardive dyskinesia
Neuroleptic 
malignant 
syndrome
Assess for fever, rigidity and tremors. Potentially fatal.
Encourage adequate water intake for all patients taking 
antipsychotics. It is a medical emergency.
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Key strategies to deal with extrapyramidal side-effects
•	 Use second-generation antipsychotics.
•	 Reduce the dose of the antipsychotic drug.
•	 Stop the antipsychotic drug and change to a different one.
•	 Add an appropriate anticholinergic agent depending on the symptoms.
•	 Give the anticholinergic drug at the lowest effective dose.
•	 Withdraw the anticholinergic drug after a period of time, usually 3 months.
•	 If symptoms recur, reinstitute the anticholinergic drug at the lowest 
effective dose.
5. Benzodiazepine warnings for patients
Benzodiazepines are useful for controlling anxiety and facilitating sleep. 
Patients like these drugs as they have rapid therapeutic effects towards 
alleviating distress. However, patients have to be educated about their various 
side-effects.
Residual sedation: The benzodiazepine group of drugs often causes significant 
sedation.
Impaired daytime performance: Sedation, combined with lowered mental 
acuity, can impair the individual’s daytime performance. This may cause 
occupational inefficiency, low productivity, and heightened risk of accidents at 
the workplace and outside.
Combining these drugs with alcohol significantly increases the adverse 
effects.
Benzodiazepines may be associated with irritability, agitation and uninhibited 
behaviour.
Benzodiazepines shorten the duration of slow-wave sleep and also decrease 
rapid eye movement sleep.
Benzodiazepines can cause anterograde amnesia and cognitive impairment.
After stopping benzodiazepines, the patient may experience rebound 
insomnia.
These drugs cause muscles to relax, which may make the person feel 
lethargic.
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Dependence: The most serious untoward effect of benzodiazepines is their 
tendency to produce tolerance, physiological dependence and psychological 
habituation. Tolerance can contribute to dose escalation.
Because the drugs can produce euphoria, they have street value.
It is not advisable to abruptly discontinue benzodiazepines after prolonged 
use, particularly high-potency types.
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